Vol.7 No.2 | March-April 2015 | New Delhi
Making! ORTHOPEDIC PARTS! Devices Reprocessing & HEALTH DATA Nutritions!for would be BRIDES The health Industry Summit CMEF! healthy diet. healthy women!
HEALTHCARE!
e
d i t
o r
i a l
h i g h l i g h t s Medical Devices & Equipment | Healthcare | Pharmaceutical Journal Vol.7 No.2 | March-April 2015 | Annual Subscription: India: Rs.2000 ; Overseas: US$250
Managing Editor
Editorial Advisory Board
Sarvjit
Alex & Lilly - Netherlands
Associate Editor & Public Relations Director
Andy McCourt - Australia
Reny
Joint Editors
Vishwapreet Amrita
Production Rakesh
Marketing & Communications Lovleen
Web Editor Ravindar
Circulation Surekha
Secretary & Legal Advisor Surinder
China Correspondents
Ying Wei / Adrian Liu
alex@vanbienen.net UK Representative
Mike Steele, MJ Marketing
20, Spencer Bridge Road Northampton NN5 5EZ Tel: +44-1604 756 100 Fax: +44-1604-750 910
For advertising, subscribing or to submit a press release, write to : D-182, PR House, Anand Vihar, New Delhi - India. Tel : +91 11 22141542 / 4309 4482 Fax: +91 11 22160635 Email: info@medicaldeviceasia.in Published, Printed and owned by: World-Wide Publications, D-182, PR House, Anand Vihar, New Delhi-110092, India and printed at Technical Press Inc. D-182, PR House, Anand Vihar, New Delhi 110092 - India. The publisher does not necessarily agree with the views expressed by the contributors, in this issue, nor do accept any responsibility for any errors or interpretation in the publication.
8 (CMEF) - Medical Technology Potentials Are Enormous 12 ENERGY EFFICIENT POWDER MIXING - Boost your productivity and energy savings 14 Siemens Healthcare presents software solution 16 HKTDC Hong Kong International Medical Devices and Supplies Fair 19 STARLED7 NX - LED lamp for operating room 20 Post Show Report: MTA2015 24 Post Show - EDICAL JAPAN with MEDIX 28 Healthy Diet, Healthy Women 29 Nutrition for Would-Be Brides 32 Quotient Clinical completes innovative first-in-human program 34 Regulatory and Clinical Factors Limiting US Non- Vascular Stent Market Growth, says GlobalData 35 Pregnancy aspects and being a New Mum 37 Hitachi Aloka Medical, Ltd. introduces EggQus AOS 100E – a compact and lightweight Ultrasound Bone Densitometry System 41 SNAPSHOT - Russian Medical Device Industry 43 Dickies® launches complete range of Medical & Healthcare Uniforms & Foot Wear in India 44 “Art & Culture” are well suited for all areas of healthcare 46 Metropolis announces launch of New Antibody Test for Major Kidney Disease 48 Fatty Liver Disease to surpass Hepatitis B & C as a cause for Liver Transplant & Liver Cancer
Invest More in Indian Medical Device Industry
T
he global size of the medical devices sector is predicted to reach US $400 billion this year. However, India ñ a key player in the global pharmaceuticals industry, of which medical devices used to be covered - is underperforming. The countryís market share stood at US $6.3 billion in 2013, contributing around 7-8 percent to overall healthcare spending in India as opposed to the 18 percent contributed by pharmaceuticals. With per capita spending estimated to be at less than US $3, it is understandable that the government feels FDI is the only way to spur domestic growth. This year, India’s medical devices industry will be opened up to 100 percent foreign direct investment (FDI). The move had been in the works for some time - India’s union cabinet met last year to discuss the reform, while the industryís regulatory framework has been tweaked several times since it was
first introduced in 2005. India presents an attractive market opportunity for global medical device manufacturers, but the country has never been able to tap into its potential as a domestic manufacturing base. Despite having a medical device market that ranks in the worldís top 20, the industry has a long history of being underresourced. The new FDI cap will spur foreign investment in Indiaís domestic medical device industry. However, companies should be careful when planning their entry strategy. The type of entity a firm chooses and the state they choose to locate it in is influential, and a thorough understanding of the industryís various regulations is absolutely necessary. When foreign entities invest in India, their investment will go through one
of two FDI routes, which affects the amount they are able to invest and the investment timeline The two routes are: The Government Route: For investment in business sectors requiring prior approval from the Foreign Investment Promotion Board (FIPB) & The Automatic Route: For investment in business sectors that do not require prior approval from the government India previously permitted 100 percent FDI in its medical devices industry through the government route, which has been widely identified as a key reason for the sectorís poor investment inflows. However, the government has said that Indiaís domestic firms will not be able to invest the kind of capital that the sector needs. Increased FDI is therefore seen as the primary way to see the industry grow. Accessing India’s medical devices
industry through an indirect route remains attractive to foreign firms. India is heavily reliant on foreign imports: 70 percent of its medical devices and equipment are outsourced from other countries, particularly from the U.S. Medical device companies that have already been approved in the U.S., Europe, Canada, Japan or Australia are able to legally sell in India. Prior to starting the import process, firms must prepare and submit a technical dossier; documents that clearly detail the type of devices intended for import and their associated risks. Devices with higher levels of risk to patients, and which necessitate greater control for safe use, will require a longer dossier and will further be subject to stricter checks. Should the dossier be found to lack all relevant information, it will likely be rejected.
Medical Device ASIA | March-April 2015 | 3
Certified according 93/42/EEC
s a g l a c i d e or m f s a e d i e Innovativ
www.ambrasistemi.it
Local and remote monitoring system for storage and distribution medical gases in hospital
Local and remote cryogenic tank monitoring system
Synthetic Air F.U. System (O2/N2) for medical air in hospital and hyperbaric chamber
Automatic change over system with recovery function for cryogenic gas tanks
DenEB Energia Pvt. Ltd. Looking for Distributors and Dealers
in India, Srilanka, Pakistan, Burma, Nepal, Bangladesh, Iran, Singapore, Thailand, Philippines, Indonesia, Malaysia, Vietnam, Qatar, Oman,Saudi Arabia, Kuwait, Turkey, UAE, Bahrain, Jordan, Israel, Syria, Cambodia and Iraq.
87-A , Aggarwal Trade Centre, Sector - 11 CBD Belapur, Navi Mumbai - 400614 Maharashtra, INDIA Tel:022 27570596 Email: info@denebsolutions.com www.denebsolutions.com www.ambrasistemi.it
The World Leader in OEM Vacuum Pump & Compressor Solutions
Serving medical, environmental, lab-science and industrial markets with innovative products for more than 50 years Find Your Solution www.gd-thomas.com Gardner Denver Engineered Products India Pvt. Ltd
305, A-wing 215 Atrium, Andheri – Kurla Road, Chakala, Andheri (E), Mumbai – 400 093. Tel: +91 (022) 658 12345 / +91 (022) 61274541 - 44 India: Manoj +91 9004282345 manoj.ahire@gardnerdenver.com | SE Asia: Michelle + 852 9170 0693 michelle.wu@gardnerdenver.com Australia: Keri +61 (0) 402 275 962 keri.mcneill@gardnerdenver.com | Korea: Eddie +82 10 7720 2584 eddie.lee@gardnerdenver.com Japan: Shiko +81 90 8051 5394 shiko.iwai@gardnerdenver.com | China: Mark +86-135-0170-935 mark.lou@gardnerdenver.com
Peripheral Arterial Disease - The next big killer Peripheral arterial disease (PAD) is the disease of the arteries supplying the limbs and the abdominal organs. It can occur either in the form of ballooning following weakening of the wall (aneurysm) or in the form of blockages following deposition of cholesterol in the arterial wall that causes narrowing of the lumen and reduction of blood supply to the part supplied by the involved artery. The most common symptom of PAD is “claudication” meaning leg pain, mostly in the calf muscles on walking and relieved by short rest and can walk the same distance again. The walking distance can gradually decrease over time and progress to pain in the foot even while resting. REST PAIN – burning pain in the distal part of the leg (foot) that is present even at rest and gets worse on elevating or placing the foot on the bed and is relieved by hanging the leg down over the edge of the bed. GANGRENE / NON-HEALING wounds also can take place when the tissue dies because of poor supply of blood. Presence of Rest pain, Gangrene or wounds is referred to as CRITICAL LIMB ISCHEMIA and signifies a high risk (50%) of loss of limb or death.
Smoking and Diabetes are the major causes of PAD. Abnormal lipids (high cholesterol), high blood pressure, obesity and certain other factors are also risk factors for Peripheral Arterial Disease. Dr. Paresh Pai, Vascular surgeon, The Vascular Clinic, Mumbai says, “Around 60% of patients with Ischemic Heart disease (IHD) and cerebrovascular disease have PAD. 50% of diabetic patients need hospitalization for infection ischemic Author: Dr. Paresh Pall diabetic feet. 25% of diabetic patients have PAD. India has the dubious distinction of becoming the diabetic capital of the world with 60 million diabetic patients in 2014. This means 15 million diabetics have PAD. 6 | March-April 2015 | Medical Device ASIA
The most important step is to avoid using tobacco in any form. Diet is another step, a proper square meal at the right times makes all the difference. Avoiding irregular diet times and eating sensibly are invaluable. Avoiding high fats esp. Saturated fats and a high carbohydrate load will help. It is also prudent to avoid fast foods, which although are tasty, contain a lot of unwanted substances which clog up the arteries. Exercise helps a lot by increasing the number smaller arteries in the extremities and can form natural bypasses. Proper exercise may eventually help improve the results of any intervention or even avoid an amputation. Treatment depends on the site of PAD and the stage. If the arteries that are affected are very small or if the blockage involves short segments, one may be able to improve blood flow without any surgical cuts. The technique used is called endovascular surgery and uses various techniques such as balloon angioplasty using simple balloons or drug eluting balloons, balloon angioplasty with stenting, directional atherectomy, etc. Advances in technology make it possible to restore circulation in big and small arteries even as far as the foot using thin wires, thin catheters (microcatheters) and newer balloons opening an entire new horizon for treating those cases that had to have open surgery with long bypass operations that took 6-8 hours in the past. It is now also possible to open up entirely blocked arteries that were previously not seen on the angiography.
Medical Technology Potentials Are Enormous The Health Industry Summit (CMEF) in Shanghai opens path to Chinese market, features products for global distribution Is China still a key driver for world economy? Some market observers underline that growth in 2014 was down to 7.4 per cent – the lowest rate within 24 years. However, this change is well within the range of the central administration’s policy aiming at sustainable dynamics. And what is even more important for the medical technology sector: As of 2013, the Chinese medical technology market sported in excess of 24 billion US-$ and the world’s highest sector growth rate – 25.9 percent. By 2020, the administration aims to increase spending in the sector to approx. 1 trillion US-$. These impressive figures provide the perfect backdrop for Reed Sinopharm’s Health Industry Summit which beckons to medtech stakeholders from around the world this spring. The current situation of China’s healthcare reform: According to results presented at the State Council of the People’s Republic on January 19, the envisaged basic system providing care to urban as well as rural regions has been established as planned. “The future target of the country’s healthcare reform is to optimize healthcare resources enabling residents to receive more effective prevention and clinical treatment while paying less money out of pocket”, explains the marketing manager of a large Chinese manufacturer who is active at a global level. Budgets from the government: As a priority, the central government will re-enforce the services capability of county-level hospitals, and support implementing a standard of care for community healthcare institutions. Furthermore, the administration is placing additional emphasis on strengthening medical IT infrastructure and telemedicine services. Influences on the market: The strengthening of countylevel hospitals and community healthcare institutions will lead to increased demand for medical devices. “Since the government aims at gradually implementing 8 | March-April 2015 | Medical Device ASIA
a system in which community healthcare institutions act as the patients’ first point of call for acute care, rehabilitation, and nursing services to reduce the number of outpatient cases in public hospitals, these institutions will need more diagnostic, rehabilitation, and hospital equipment”, according to the marketing manager. Further drivers in the market: In addition, aims of the central administration include installing at least one hospital with comprehensive services and one traditional Chinese medicine (TCM) hospital in each county. Also the government encourages the involvement of social capital in improving medical services, and creation of new non-profit healthcare institutions is encouraged based on the cooperation of social capital and public hospitals. The government will support those hospitals built with social capital to increase their number of beds. Drivers of the medical devices market: In China, currently devices made by Chinese manufacturers are mainly sold to public hospitals below category III – which is the top hospital category in the country – and to private hospitals. However, some large innovative domestic manufacturers have been successful in entering the top category market thanks to their strong technical and financial resources, impinging on the monopoly of imported devices category III hospitals. Regions make a difference: Due
to the unbalanced economic development in the various regions of China, healthcare resources mostly accumulate in the coastal areas, causing a large gap regarding medical technology and medical services skills between the coast, tier 1 cities, and the rural west of the country. In that rural area and parts of the underdeveloped provinces, medical equipment is generally used for a longer period without replacement. Much of the equipment is comparatively old, and penetration of high-end and valueadded imported devices is low. With the continuous large investment from both central and local administrations at the basic level of care, a larger number of county-level hospitals and community healthcare institutions will refurbish their infrastructure and purchase new medical equipment. “As far as middle and high-level equipment is concerned, for various reasons Chinese hospitals still prefer to buy imports. Both domestic and imported medical equipment will have an opportunity to grow by a large extent in China in the upcoming years”, explains the manager. High-end medical equipment used in China is mostly from foreign manufacturers; in the middle-high end range imports own 80% market share; in the middle to low end sector, imports have 40% while national manufacturers take 60% of the market, and low-end equipment used in China comes mostly from national manufacturers.
decision makers and end users where real trends are shaped, to institutions and R&D firms where the next big opportunities are defined. Ultimately, underlines Wang, the needs of the market and the technology benefits shape the opportunities of the market in China.
Features Chinese hospitals focus on: Research and development of medical equipment requires huge staff and financial resources, with the added difficulty of highly restricted access and IPR (intellectual property rights) protection similar to the pharmaceutical industry. According to the marketing manager, roughly 80% of the domestic manufacturers focus on producing low value-added medical disposables, general surgical instruments, rehabilitation equipment, home-use devices, and low-end diagnostic equipment. Products with high value are mainly imports, which leaves hospitals with little choice. Summit to present this market information: From May 15 to 18 in Shanghai, the Health Industry Summit in Shanghai – previously under the name of China International Medical Equipment fair (CMEF) – will sport more than 100 conference sessions, with more than half focusing on various fields of medical technology and market trends. “The conference portfolio will include the China Integrated Medical Imaging Summit, the In-Vitro Diagnostics China Summit, and many more”, explains James Wang, marketing director of the Summit. The China Healthcare Investment Summit – the key conference – will focus on topics such as China’s Health Reform and Healthcare Service Development, New Trends in Health Industry Regulations, and the Creation of the Intelligent Healthcare Ecosystem, drawing top level participation as business leaders and investors contemplate the next big moves related to investing in the booming China health market, outlines Wang. Entering the market: CMEF has long been the leading medical equipment event in Asia, Wang goes on to say. “While sourcing and trading activities may attract the crowds, however, it is for companies wishing to enter the Chinese market that CMEF plays a vital role: Finding the best partner and picking the right product suitable for the market makes all the difference between growing rapidly and losing out”. No other event in China provides a similar exposure to the thousands of key hospital
International players at the Summit: Over 3,000 suppliers and nearly all of the key players in the market are represented at the show – including, e.g. GE, Siemens, Philips, Mindray, Neusoft, Toshiba etc. – from the U.S., Japan, Europe, Asia Pacific, and of course China. New set-up of the congress and tradeshow and investment environment: The Health Industry Summit combines the medical and pharmaceutical value chains into one mega event which explores a multitude of synergies including distribution, international trade, and investment opportunities. “Investment in the health sector is on the rise, with 255 investments in the health sector in China worth 19.5 bn RMB from January to October 2014, representing a major
jump in growth compared to 5.3 bn RMB in 2013”, says Wang. The event comes at the perfect time when China announces major investments and developments in the health sector, including in the health services and new technologies in health IT systems and digital health platforms. “In the context of the envisaged size of the health industry in the country at 8 trillion RMB by 2020, the central administration has made steps to speed up licensing and registration for health food and nutrition products as well as other international technologies in the medical and pharmaceutical fields. Favourable tax policies on selected product imports are also on the agenda between key countries and China”, is Wang’s overview of trends. International buyers: More than 10,000 international buyers from more than 140 countries will join the event. The health industry Summit will effectively combine the world’s largest integrated health expo (with 280,000 square metres of exhibition space and an estimated 200,000 visitors) with a full Summit program to help the health industry in China to link up with its international counterparts. The event looks to be a highly anticipated prelude for larger changes and greater things to come in the health sector and the worlds of medical technology and pharmaceuticals. v
About the Health Industry Summit Location: Shanghai, China Date: May 15 to 18 Focus: medical technology and pharmaceuticals Expected audience: 10,000 international buyers, 280,000 square metres of exhibition space, total 200,000 visitors) Further information: http://www.thishealthsummit.com/en/index.jhtml Medical Device ASIA | March-April 2015 | 9
Expanding the Care Continuum through SMART Homes and Intermediate and Long-Term Care (ILTC) Services HOW AGED WILL SOUTH EAST ASIA LOOK IN 2030? SINGAPORE 2 working citizens supporting 1 elderly (2015: 4.9 workers to one elderly) MALAYSIA Will become an ageing population country, with 4.9 million (~15% of its population) 60 and above THAILAND Over 13 million (~19% of its population) will be 65 and above PHILIPPINES Over 14 million (~11% of its population) will be 60 and above INDONESIA 6.4 working citizens will support one elderly. (2010: 13 workers to every older person)
With pressing challenges bearing down on Asia such as rapidly ageing populations, shortages of hospital beds in acute care settings as well as low accessibility to care in rural regions, SMART homes and Intermediate and long-term care (ILTC) services enable remote care and take pressure off hospitals by expanding the care continuum through services such as step-down care. They are emerging trends that are here to stay.
SHORTAGE OF HOSPITAL BEDS AND LONG WAIT TIMES IS A GLOBAL ISSUE CHINA: In China, it is very common to see people waiting for hours in hospitals to see doctors. Now four provinces are introducing medical reforms to help deal with long wait times. For example, top hospitals in Anhui have cut registration numbers by half and are sending experienced medical staff to smaller institutions in order to reduce workload, prevent overcrowding and provide better service for patients. (Source: CCTV-America) GREAT BRITAIN: A&E waiting times in England are the worst in a decade. While the government has set a target of 95% of patients to be treated or discharged within four hours, the latest figures for Q1 2015 show that this target has been missed by the biggest margin in a decade at 91.8%. (Source: The Guardian) AUSTRALIA: Canberra Hospital’s emergency department has reported in March 2015 that they have close to 28 people waiting for treatment at one time, with some being treated in nursing corridors. ACT Health’s first quarterly report for 2014-15 also found that the waiting times at Canberra and Calvary hospitals’ emergency departments have increased on an average from 39 minutes to 49 minutes. (Source: Canberra Times)
LOW ACCESSIBILITY TO CARE IN RURAL AREAS
50% of the World’s Population Live in Rural Areas, but Fewer than 38% of Nurses and 25% of Doctors Work There – UN World Health Organization
China: 80% of government health expenditures go to urban areas, but only 45% of China’s population lives there.
Myanmar: In rural areas – where 70% of the country’s 58 million people live – patients travel hours and sometimes an entire day to reach hospitals or clinics in towns.
Philippines: Twenty-four babies die for every thousand infants born in the urban areas, while the infant-mortality rate in rural areas is higher by 50 percent: 36 babies die for every thousand live births.
Attend the HIMSS AsiaPac15 Conference to learn about how these problems are being solved! Visit www.himssasiapac.org/15 for more information. Contact us. General Enquiries
Exhibition & Sponsorship
Program Content
Registration
Media
SIMON LIN, CEM
GABRIEL SIM
SARAH GRANT
AGNES HOW
MELISSA LEONG
General Manager
Business Development Director
Education Manager
slin@himss.org +65 6664 1188
gsim@himss.org +65 9299 0802
sgrant@himss.org +65 6664 1183
Coordinator, Administrative & Meeting Services
Manager, Marketing & Strategic Relations
ahow@himss.org +65 6664 1189
mleong@himss.org +65 6664 1182
ART Healthcare
transforming how we manage health ARTHospital ARTCareSingapore
ARTHome
by
ART Healthcare
ARTExchange
ARTConsumer
ARTData
Confirmed Featured Speakers: Dr. Suriya Wongkongkathep Deputy Permanent Secretary Ministry of Public Health, Thailand Dr. Shinsuke Muto, PhD, EMBA President, Tetsuyu-Kai Institute Medical Corporation Executive Advisor for Information Policy, Ministry of Health, Labour and Welfare of the Japanese Government
MARINA BAY SANDS, SINGAPORE · 6 -10 SEPTEMBER 2015 6 September: CPHIMS Exam 7-9 September: Conference & Exhibition 10 September: Masterclasses & Hospital Tours
/15
Get social with us! twitter.com/HIMSSAP Himss Asia Pacific
Russell P. Branzell, FCHIME, CHCIO President & Chief Executive Officer College of Healthcare Information Executives (CHIME), USA Dr. Jack Cochran, FACS Executive Director The Permanente Federation, LLC
+ many more!
Contact us. Exhibition & Sponsorship GABRIEL SIM Business Development Director gsim@himss.org +65 9299 0802
Registration AGNES HOW Coordinator, Administrative & Meeting Services ahow@himss.org +65 6664 1189
Organized by:
Supported by:
AP15_Mktg_Advert_AHHM_V02.indd 1
Dr. Fazilah Shaik Allaudin Deputy Director Telehealth Ministry of Health, Malaysia
Find out if you are eligible for the HPF fund by AIC. Save up to 90% of your conference fees today through the Healthcare Productivity Fund (HPF) by AIC. Visit aic.sg/hpf to find out more.
Held in:
In support of:
15/4/2015 1:02:22 PM
ENERGY EFFICIENT POWDER MIXING
Boost your productivity and energy savings shear in a small area, the Hybrid Powder Mixer creates high dynamic shear in several different steps, which require less energy to ensure complete dissolution of the powder. The Hybrid Powder Mixer can also be used as part of an efficient Cleaning-in-Place (CIP) system.
YOU BENEFIT BY REDUCING • Installation costs: A unit with only one electric motor for powder mixing, pumping and CIP. • Operating costs: Low power consumption, providing up to 50% energy savings. • Maintenance costs: Service is simplified due to fewer components. • Processing time: Fast and homogenous powder mixing at high dry matter concentration.
Alfa Laval TK20 The new Alfa Laval TK20 semi-welded gasketed plate heat exchanger is optimized to deliver the best in performance and reliability for heating and cooling of aggressive media. With its compact and leakage-proof design, flexible configuration and high serviceability, it is the optimal solution for applications where high efficiency is key.
About Alfa Laval Increased productivity and energy savings are both important targets in most industries. Together with our partners throughout the world, Alfa Laval is committed to help you reach these targets and beyond.
High rate of dynamic shear mixing Mixing and pumping both wet and dry ingredients into a homogenous blend can - depending on viscosity - require up to four separate electric motors, consuming a lot of energy. The Alfa Laval Hybrid Powder Mixer can accomplish the same using only a single motor drive, including efficient mixing in the associated production vessel, when used in combination with the Alfa Laval Rotary Jet Mixer. The Hybrid Powder Mixer combines pump and powder dissolving technologies in a single versatile unit. It is the only hygienic powder mixer capable of drawing powder into the unit while simultaneously pumping the resulting process liquid at pressures up to 4 bar, making the need for a separate discharge pump obsolete. It effectively preblends the powder and liquid before the mixture enters the high-shear stage, which contributes to faster and more effective dissolution. While other inline powder mixers create mechanical 12 | March-April 2015 | Medical Device ASIA
Alfa Laval is a leading global provider of specialized products and engineering solutions based on its key technologies of heat transfer, separation and fluid handling. The company’s equipment, systems and services are dedicated to assisting customers in optimizing the performance of their processes. The solutions help them to heat, cool, separate and transport products in industries that produce food and beverages, chemicals and petrochemicals, pharmaceuticals, starch, sugar and ethanol. Alfa Laval’s products are also used in power plants, aboard ships, oil and gas exploration, in the mechanical engineering industry, in the mining industry and for wastewater treatment, as well as for comfort climate and refrigeration applications. Alfa Laval’s worldwide organization works closely with customers in nearly 100 countries to help them stay ahead in the global arena. Alfa Laval is listed on Nasdaq OMX, and, in 2014, posted annual sales of about SEK 35.1 billion (approx. 3.85 billion Euros). The company has about 18 000 employees. For more information, please visit: www.alfalaval.com
To study the phenomena of disease without books is to sail an uncharted sea, while to study books without patients is not to go to sea at all. - William Osler
IncorporatIng
12 - 13 May Prince Hotel and Residence | Kuala Lumpur, Malaysia Pre-conference Lean Focus Day: 11 May 2015 | Post-conference Workshops and Site Tour 14 May 2015
Featuring Speakers from Malaysia Ministry of Health, Singapore National Health Group and the Hong Kong Hospital Authority
Dr. Cheung Wai-lun, Allen Director (Cluster Services) Hospital Authority, Hong Kong
Dr. Feisul Idzwan Mustapha Public Health Physician, NonCommunicable Disease Section, Disease Control Division Ministry of Health, Malaysia
Dr. Nor Akma bt Yusuf Deputy Director, Hospital Management Services Unit Ministry Of Health Malaysia
Ho Khai Leng Group CIO National Healthcare Group, Singapore
Featured top Hospitals Include:
Brought to you by:
+65 6722 9388
Supporting partners:
enquiry@iqpc.com.sg
www.healthcareweekasia.com
Siemens Healthcare presents syngo. via RT Image Suite software solution · Flexible multimodal image viewing for sound treatment decisions · Efficient contouring of tumor tissue and neighboring organs at risk
A
t the third forum of the European Society for Therapeutic Radiology and Oncology (ESTRO) in Barcelona, Siemens Healthcare will be presenting a new software solution for radiation therapy: syngo.via RT Image Suite has been specially developed to make it easier for radiation oncologists to evaluate a range of clinical images such as MRI, CT, PETCT, and cone beam CT images, and to subsequently contour tumors and the surrounding organs to be spared. This means that the available image data, independent of the modality, can be used more effectively to define the optimal patient-specific radiation therapy strategy. Today, existing software such as virtual simulation or treatment planning solutions are only partly able to accommodate the increasing number and diversity of images. Often, only two image series can be displayed at the same time – far too few if the clinician is looking to have a comprehensive view of the clinical situation using several different MRI contrasts, CT and PET images, and 3D and 4D views with the aim of deciding on the best-possible treatment approach. This is different with the new syngo.via RT Image Suite. Based on syngo. via, Siemens’ comprehensive image viewing and processing software solution, syngo.via RT Image Suite has been specifically developed to accommodate the increasing number and diversity of images used in radiation oncology: Up to eight fused image series can be displayed on up to four image panels at the same time. Dual Energy CT images, different PET tracers, and different MRI image contrasts – which are particularly helpful when diagnosing prostate cancer, for example – can be visualized at the same time, as can all image data 14 | March-April 2015 | Medical Device ASIA
for moving tumors, for example in the liver or lungs. Syngo.via RT Image Suite therefore offers radiation oncologists a detailed basis for deciding on the therapy approach, evaluating courses of treatment, and possibly adapting the treatment.
and also as an upgrade for installed Siemens Healthcare systems. In addition to clinical images from the various Siemens imaging modalities, diagnostic images from other manufacturers can also be viewed and processed.
A well-founded assessment of clinical situation is just the first step on the path to more precise radiation therapy. The subsequent, exact contouring of the tumor plays just as important. Here, too, the syngo.via RT Image Suite helps by making it easier and quicker to contour the tumor tissue and neighboring organs, for example, via the automatic, parallel contouring of marked areas in several image series. Tumors can be quickly contoured, even in moving 4D CT datasets for the lungs. And if an adaption of therapy is required during the course of treatment, the software application supports fast recontouring of the tumor boundaries.
Magnetom RT Pro edition supports MRI trend in radiation therapy planning
Clinical images contoured using syngo.via RT Image Suite can then be transferred to treatment planning systems such as Eclipse from Varian Medical Systems – Siemens Healthcare’s strategic partner in radiation therapy – for dosimetric planning. Particularly in curative approaches – which is increasingly the case in breast or prostate cancer patients, both constituting a large proportion of oncological diseases – precise radiation dose planning is extremely important to avoid side effects in neighboring organs, which are potentially at risk. Syngo.via RT Image Suite is available with new imaging systems
Magnetic resonance imaging (MRI) – due to its excellent soft-tissue contrast – is gaining importance as the basis for radiation therapy decisions. Therefore, Siemens Healthcare will also be presenting an innovation in this field at the ESTRO Forum: The Magnetom RT Pro edition encompasses an MRI scanner with a particularly spacious open bore of 70 centimeters – either the 1.5-tesla Magnetom Aera or the 3-tesla Magnetom Skyra – and special equipment for radiation oncology. This includes the RT Dot Engine, among others, whose protocols are specially tailored to radiation therapy workflows. In addition, Siemens Healthcare will present the new RT Pro edition for the Somatom Definition AS Open computer tomograph – now with new functionalities. These include a new, highly effective iterative algorithm for metal artifact reduction: iMAR can significantly reduce disruptive image artifacts caused by implants, artificial joints or pacemakers, which are found in more and more patients. Therapies can therefore be prepared and dose calculated based upon much more detailed information for a larger number of radiation therapy patients.
India’s definitive exhibition & conference on products & services that aid the inclusion of differently abled
19-20-21 November 2015 Bombay Exhibition Centre, Goregaon (E) Mumbai, Maharashtra
Highlights 150+ exhibitors from across the world Eminent speakers at 2 day Asia Rehab Summit Knowledge support from leading sectoral associations Intensive skill development workshops for professionals in the sector Training sessions for the differently abled and their families
www.IndiaRehabExpo.com
For more details, contact : Japesh Thakur +91 9599389544 japesh@infinityexpo.in
HKTDC Hong Kong International Medical Devices and Supplies Fair
Follow latest market trends, Explore Medical Industry’s Advancements The 6th HKTDC Hong Kong International Medical Devices and Supplies Fair will run from 18 to 20 May 2015 at the Hong Kong Convention and Exhibition Centre. The event is expected to attract around 240 exhibitors from 14 countries and regions to promote medical products as well as related services. In 2014, the fair attracted more than 9,600 buyers from 54 countries and regions, an increase of 17% from 2013 edition. Buyers appreciate this valuable opportunity to connect with international exhibitors to browse and source their diversified products. 16 | March-April 2015 | Medical Device ASIA
I
n 2014, Hong Kong’s total exports of medical and healthcare equipment increased by 1.3% compared with 2013, reaching the amount of USD1.6 billion, with the top five markets of the Chinese mainland, the United States, Japan, Germany and the Netherlands. There was an impressive growth in exports to mature markets such as United Kingdom (+35.1%) and Japan (+27.1%).
Satisfying market trend and demand According to the United Nations, the older population is, and will remain, predominately female. Globally, women outlived men by 4.5 years on average in 2014.
As a result, women made up 54% of those aged 60 or above and 62% of those aged 80 or above. These trends have resulted in an increasing demand for medical and healthcare products designed for the aging population. According to the latest figures from World Health Organisation, the total global expenditure for health is now more than USD6.5 trillion a year. Facing the phenomenon with constant growth of aging population, especially for women population, the demand for physiotherapy and medical beauty products have increased. The Medical fair provides an unrivalled platform for buyers to discover all kinds of medical
and health-related technology, equipment, devices and supplies. Physiotherapy Zone was introduced at the 2014 fair. It returns to cater to a growing demand for items such as therapy mattress, therapy light, physiotherapy plinth, physiotherapy massage equipment. The Medical Cosmetology Zone also remains to be the highlight at the fair, showcasing equipment such as IPL (intense pulsed light) devices and laser devices for beauty and dermatology applications.
Specialised Product Zones For the convenience of our buyers, a variety of equipment, technology and services are categorised into major zones, including the Rehabilitation and Elderly Care zone, in response to the arising demand from these two areas include patient-monitoring systems, orthopaedic equipment and wheelchairs, which are in keen demand. The constant demand for the most updated specialist electro-medical equipment and medical technology makes the Hospital Equipment zone an attraction for buyers seeking ultrasound, imaging and anaesthetic equipment and surgical instruments. Market sees increasing needs for household medical
products. Buyers can visit the Household Medical Products zone to look for portable medical devices, which also allow users to conduct point-of-care medical tests or treatments. Amazing Life Development Company will be showcasing a foot masseur pillow. When our feet blood circulation is low or if our lower bodies’ circulation has disorders, it will lead to internal organ functions declination. The foot masseur pillow can help stimulate blood circulation by rhythmic pulsation or barometric pressure massage. JMS Medical Company will also be displaying various household medical products at the zone, including: blood pressure monitors, oximeters, non-contact infrared thermometers, beauty devices, etc. Other exhibit categories include Accident and Emergency Equipment; Building Technology and Hospital Furniture; Chinese Medical Devices; Communication, Systems and Information Technology; Diagnostics; Electromedical Equipment / Medical Technology; Laboratory Equipment; Medical Components and Materials; Medical Supplies and Disposables and Medical Textiles.
Distinguished speakers attending the Convention There creates strong synergy with the concurrent Hospital Authority Convention 2015, one of the region’s largest events for healthcare professionals. Over 4,000 delegates are expected to attend, with about 90 distinguished overseas and local speakers to share their knowledge and insights and interact with delegates. It aims to promote the sharing of knowledge and experience on clinical advances and approaches to modern healthcare service, and facilitates exploration and discussion of contemporary concepts among healthcare professionals and stakeholders. Fair website: Hong Kong International Medical Devices and Supplies Fair: http://www.hktdc.com/fair/hkmedicalfair-en
About the HKTDC A statutory body established in 1966, the Hong Kong Trade Development Council (HKTDC) is the international marketing arm for Hong Kong-based traders, manufacturers and service providers. With more than 40 global offices, including 11 on the Chinese mainland, the HKTDC promotes Hong Kong as a platform for doing business with China and throughout Asia. The HKTDC also organises trade fairs and business missions to connect companies with opportunities in Hong Kong and on the mainland, while providing information via trade publications, research reports and online. For more information, please visit: www.hktdc.com.
Medical Device ASIA | March-April 2015 | 17
Transasia Bio-Medicals Ltd. introduces new range of biochemistry reagents
A
t India’s leading diagnostic company, all efforts are continuously on, to reinvent the available technologies as well as develop new products/ chemistries, with an aim to improve the quality of healthcare. In more than 35 years of its existence, Transasia has provided doctors world over, with quality systems backed with superior services. Recently, Transasia has expanded its product portfolio of biochemistry reagents by adding three new products: • ERBA Lipase XL system pack • ERBA Enzymatic Creatinine system pack • ERBA Bilirubin DCA (Total & Direct) system pack
Acetoacetate in fact, reacts more rapidly with picrate than creatinine. Enzymatic creatinine, a new method for estimation is widely accepted as one of the most accurate routine methods currently available. Several studies have concluded that enzymatic method is suitable for routine measurement of serum creatinine, particularly for diabetic ketotic patients, neonates, and patients receiving cephalosporins. Comparison (by independent ‘t’ test) and the agreement between two methods (ICC) of the Serum Creatinine values obtained by Enzymatic Methods and Kinetic Jaffe’s method:
ERBA Lipase XL System Pack High amount of lipase in the blood could be a result of damage to the pancreas or a blockage in the tube leading from the pancreas (pancreatic duct) to the beginning of the small intestine. A lipase test is done to: • Check for pancreatitis and other diseases of the pancreas • Ensure that the treatment for pancreatitis is working • Check for cystic fibrosis or evaluate if the treatment for it is working Benefits of ERBA Lipase XL system pack: • Readily adaptable, ready to use liquid stable assay-ideal for most open chemistry analyzers • Preferred chromogenic substrate 6’ methylresorufin ester used as a direct assay without second reaction, unlike the 1 & 2 diglyceride method • Compatible with both serum and plasma samples • Ten fold reduction in interference from triglycerides in comparison to 1 & 2 triglyceride method • Virtually no interference from cholesterol • Results in ten minutes only • Economical cost per test
The ERBA enzymatic creatinine system pack offers• Improved specificity • Smaller sample volume • High throughput • No interference by glucose, acetoacetate, and cefoxitin • Negative interference by bilirubin, which depends on both creatinine and bilirubin concentrations.
Pack Presentation- R1-2 x 44 ml/R2-2 x 11 ml
Pack Presentation: R1- 5 x 30ml/ R2-5 x 10 ml
ERBA Enzymatic Creatinine system pack Creatinine has been found to be a fairly reliable indicator of kidney function. The kidneys maintain the blood creatinine in a normal range. Elevated creatinine level in the blood signifies impaired kidney function or kidney disease. It is for this reason that standard blood tests routinely check the amount of creatinine in the blood. Routine clinical biochemistry laboratories use several methods for the estimation of serum and urinary concentrations of creatinine, most of which are based on the Jaffe’s reaction. However, there are major analytical problems associated with the use of the Jaffe’s reaction, in particular those relating to positive and negative interference by chromogens. More than 50 chromogenic interfering substances have been documented. Common among them are glucose, acetoacetate, bilirubin, and cefoxitin. Both glucose and bilirubin inhibit the reaction between creatinine and alkaline picrate. Glucose slowly reduces picric acid to picramate. While bilirubin, under alkaline conditions, is oxidized to biliverdin, causing a decrease in absorbance at 520 nm. Acetoacetate and cefoxitin, conversely, react directly with alkaline picrate and cause positive interference. 18 | March-April 2015 | Medical Device ASIA
ERBA Bilirubin DCA (Total & Direct) system pack Conventional methods for the estimation of bilirubin have limitations when it comes to the diagnosis of neonatal samples. One of the major disadvantages of the routine Diazo Sulfanilic Acid method is that the sulfanilic acid has to be diazotized each time a series of bilirubin determinants are performed. This process is apparently a benign procedure, leading to discrepancies in bilirubin determination. On the other hand, In the DCA method, the salt is already diazotized.Hence, it proves to be highly stable and accurate in performance. The new DCA method does not interfere with Hb and TG and is an exceptionally simple technique, easily adaptable to all automatic analyzers. The new ERBA Bilirubin DCA system pack offers: • Liquid-stable, ready-to-use reagent • Linearity upto 14.75 mg/dl • Measuring range- 0.064-14.75 mg/dl • No interferences by lipemia, hemoglobin and ascorbic acid • Convenient reagent packing Pack Presentation: R1-6x44 ml/ R2-3x22 ml
STARLED7 NX - LED lamp for operating room STARLED7 NX is the operating lamp granting the best working conditions to surgeons and medical staff.
T
he new NX series of our STARLED lamps meets the highest quality standard requirements.STARLED7 NX produces a perfect IR-free light, with an excellent colour temperature and low consumption suitable for every situation. The Made in Italy design grants visual comfort, practicality of use and compatibility with laminar flows. STARLED7 NX boasts an excellent light quality. The special optics of its LEDs, realized by ACEM, generates a shadowless, clear and homogeneous light assuring visual comfort and best working conditions both for the surgeon and for the medical staff. Thanks to its next generation LEDs, the lamp can produce a perfect illumination under every condition generating a IR-free light, an excellent colour temperature and a practically endless life cycle at low consumptions. The lamp is composed by 57 next generation LEDs circularly placed and splitted into 7 reflectors (with 7 LEDs each one) and other 8 LEDs radially positioned around the handle. STARLED7 NX produces a high illumination level of 160.000 lux. The colour rendering index of 95 and the colour temperature of 4.500 °K allow to reproduce the exact chromatic scale of the colours of the human body. The lamp is provided with ACRIS, the innovative system realized by ACEM that ensures, by the use of a microprocessor, the control of electrical curves typical of LEDs to remain unaltered over the time but maintaining a long life cycle (about 50.000 hours).
STARLED7 NX assures: • High quality illumination level for each kind of surgery • Colour temperature representing the contrast of the surgical area perfectly • Colour rendering index of 95 (CRI) • Clear luminosity at 160.000 lux • Colour temperature of 4.500 °K • Ergonomics for an extraordinary simplicity of use and easy positioning for the medical team • Exceptional duration with easier management and low consumptions
STARLED7 NX is provided with: • ACRIS, a smart system created by ACEM • A special system to adjust the light field dimension without mechanical parts through an optical-electronic management • A revolutionary I – SENSE® control system • An innovative LIGHT – UP system that, thanks to the special light beams coming from the upper part of the lamp, assures adjustable illumination levels according to the different use and particularly suitable for minimal invasive surgery.
FOCUSED AND AMBIENT LIGHT In order to achieve a correct illumination according to the different needs STARLED7 NX can produce a FOCUSED and AMBIENT light. Thanks to the special optics realized by ACEM, the light field focusing system adjusts the light spot diameter accurately assuring an excellent sharpness of details in the operating area. The light field dimension adjustment without mechanical
parts is possible through an opticalelectronic management that grants a steady, homogeneous, shadowless and reliable illumination of the operating field in every situation particularly suitable for deep cavities. AMBIENT light is managed by the LIGHTUP system, a technology created by ACEM that produces adaptable and adjustable illumination levels according to the different uses thanks to the special light beams coming from the upper part of the lamp. This light allows to visualize the operating field as well as the surrounding environment clearly and is particularly suitable for minimal invasive surgery and for the preparation and treatment during the operation, monitoring of the patient and microscope operations.
Ergonomic, practical and functional design Comfortable and light to move, thanks to its central handle, STARLED7 NX is practical also for the medical team who can move it from the lateral handles assuring stability and constant illumination even during the movement. STARLED7 NX has been manufactured with a smooth and resistant material that makes cleaning quick, easy and complete. On demand, the removable and sterilizable central handle can house a video camera shooting the surgical operations accurately (the video camera can be placed on a separate arm alternatively). The lamp shape assures visual comfort and is particularly suitable for laminar flows in the operating room. The design is practical, functional and ergonomic. Thanks to AVSM system (Acem – Video – System – Management) STARLED7 NX is compatible with all the cameras and monitors offered by ACEM. STARLED7 NX functions are managed by the handy, digital and easy-to-read I–SENSE® control panel positioned on the cardanic structure and adjusting: • ON/OFF function • Light intensity • SIZE - Light spot diameter dimension (light beam focusing) • ENDO - Light for endoscopy • DOF - Depth of field – for a full visualization of the operating field and deep cavities • SYNC – (optional) Mode to synchronize controls among the combined lamps: STARLED7 NX double (twin dome configuration) and STARLED7 NX with STARLED5 NX or STARLED3 NX. The SYNC mode grants simplicity of use saving time and giving the possibility of being managed by a single operator. The precise and easy-to-read I–SENSE® system is functional, simple and easy to clean. The optional remote control is useful to manage all the functions of the lamp from a remote position offering the end-user better efficacy and practicity.. For more information, please contact: ACEM SpA Medical Company Division Via della Tecnica 29 - 40050 Argelato, Bologna – ITALY Ph. +39 051 721844 Fax +39 051 721855 info@acem.it www.acem.it Medical Device ASIA | March-April 2015 | 19
MTA2015 Reflected Industry’s Shift Towards High Value-Added and High-Tech Manufacturing As the industry undergoes a restructuring and gears itself towards high value-added and hightech production, companies are confronted with a pressing need to rise above traditional boundaries, by embracing new technologies and acquiring new knowledge.
I
n keeping abreast with current industry trends and newest technological innovations, MTA2015, which came to a close on 17th April 2015, provided an ideal platform for Asian companies to access the latest hightech precision engineering and machine tool technologies available in the global marketplace. Technologies for 3D printing and robotics have been earmarked by the government as the future of manufacturing. At MTA2015, exhibitor showcases dedicated to demonstrate these capabilities were extremely wellreceived. In addition, equipment and solutions designed to cater to high-value sectors of Aerospace, Automotive and Oil & Gas sectors were also highly sought after.
20 | March-April 2015 | Medical Device ASIA
Flexspeed Technology is one such exhibitor showcasing solutions catered for the Oil & Gas sector. Commenting on the event, the director, Mr. K. Balanagendra Rao said, “MTA is a very good platform where our existing and potential customers can come and see the new technologies and where we present new ideas, especially for those in the aerospace and oil and gas industries. We sold some machines for the oil and gas industry where the technology used is very important for the sector. We are very pleased with the results.”
3D printing and robots in the spotlight The 3D Printing Technology tours were very popular with
attendees and highlighted the flexibility of the technology for applications across industries such as aerospace, automotive and oil and gas. Creatz3D, DKSH Technology, EOS, Eye-2-Eye Communications and Renishaw were some exhibitors who shared their expertise in the field with visitors. Besides displaying a model tilted rotor airplane and a concept car, academic institutions – the Additive Manufacturing Innovation Centre (AMIC) at Nanyang Polytechnic (NYP) and the Singapore Centre for 3D Printing at Nanyang Technological University (NTU), also showcased products that were wholly 3D printed from materials such as metal.
“3D printing technology has advanced over the years and there is great potential for its adoption in Asia. The focus on 3D printing at MTA has certainly helped to generate and increase awareness of the latest advances in the technology. We are pleased to be a part of the 3D printing technology tours that were organised at the event. These have added another dimension to the event and enlivened the knowledge sharing and business collaboration aspects,” remarked Mr. Steve Bell, General Manager – ASEAN of Renishaw (Singapore). Mr. Louie T. Fuster, Board of Director from the Philippine Die & Mold Association Inc (PDMA), who led a group delegation to MTA2015, highlighted the 3D printing aspects of the event and said, “PDMA is happy with our group delegation visit to MTA2015 this year. It was time well-spent as our delegates were
able to see the latest technologies in the market and met new suppliers from Germany and UK. In particular, the group was especially impressed with the showcase of 3D printing technology by industry leaders. We have learnt much from our trip this time and wish that we had more time to interact with the exhibitors. We hope to visit again in 2017.” With demonstrations almost every hour, robots from ABB, Epson and Yaskawa had the show floor buzzing with excitement. Attendees got a first-hand experience of ABB’s welding robot, whilst Epson and Yaskawa showcased the precision of their robots, which were programmed to scan items and pick these up in a fraction of the time it takes humans to do. The demonstrations provided attendees with opportunities to expand their knowledge about robotic solutions and how these
can enhance productivity for manufacturers. Elaborating on the solutions, ABB’s Mr. Ang Boon Hua, Local Business Unit (LBU) Manager, Robotics of the Discrete Automation and Motion Division said, “Robots improve productivity by enabling manufacturers to redeploy or upgrade their workforce, and we see the business potential for the Asian manufacturing industry. MTA is a timely platform for us to share our knowledge with manufacturers as well as enhance our business networks with partners and potential customers from the region.”
Resource platform for industry players MTA was also a premier sourcing ground for many industry visitors who came to seek out the latest technologies available. Deals were made, with “Sold @ MTA” signs prominently displayed on many machines and equipment from
exhibitors such as Hong Chek, Ichi Seiki, Metalis, NPC, Taipei Industries and Tsugami Universal. Exhibitors were also seen busy networking with attendees at their booths and the discussion areas set up to facilitate meetings. “Previously, I should say MTA was like a machine tool supermarket where we display machines and look for buyers to close the order. But since 2013, the show has evolved, and the exhibits and machines showcased follow market requirements very closely. You can see machines on the show floor that are relevant to the aerospace, as well as oil and gas industries. We see many new machines at MTA this year. At Ichi Seiki, we saw the trend and brought in the full five-axis machine, which enables simultaneous cutting and can be easily automated to enhance efficiency and productivity. The machine caters not only for oil and gas, but also for the high-end
Medical Device ASIA | March-April 2015 | 21
MTA 2015 SHOW PREVIEW
Delegates at the inaugural Future Factories and Manufacturing Asia Conference, held alongside MTA2015
DMG MORI SEIKI senior management welcoming Mr Lee Yi Shyan, Senior Minister of State for Trade & Industry and National Development to their booth
moulds for the aerospace sector. I can see that the exhibitors and organiser have put in a lot of effort to make the event even more relevant to market requirements and future needs,” commented Ms. Jane Low, Executive Director of Ichi Seiki, Singapore.
had a chance to source from new exhibitors who cater to their engineering and machining needs. The association has always made it a point to form group delegation to visit the MTA exhibition and will continue to support the next edition.”
“This is the first time I am attending MTA. I think it is quite interesting and good to be able to see most machine suppliers under one roof, where we can meet more people and increase our knowledge. The equipment showcased is all updated and most of them use very advanced technology which we have never heard of, and we were surprised that this technology can help us and that is an eye-opener for us. We bought a machine from Flexspeed at MTA and we are looking at buying more machines from other suppliers as well. I think MTA is a very knowledgeable and resourceful event,” said Mr. Dwaraka Malekar, Procurement Manager of Tech Offshore Marine, Singapore. Mr. Sonny Nizam, Assistant General Manager from Calsonic Kansei Malaysia added, “I came to MTA2015 to look at new
technologies and find out what is available in the market. We found many machine makers, including DMG Mori, and were pleased that MetrologyAsia featured the latest equipment. The exhibition also gave me the opportunity to meet our existing suppliers and source for new ones. We currently get our micrometers from Japan, but managed to find a new supplier from Singapore at MTA2015!” Over 20 group delegations from Indonesia, Malaysia and Singapore attended MTA2015. Groups from the Federation of Malaysian Foundry and Engineering Industries Associations, GE Aviation, Rolls Royce, Pratt & Whitney, amongst others, were at the event to check out the technologies and solutions available. Mr. Lee Ah See, President of the South Johor Foundry & Engineering Industries Association (SJFEIA) said, “MTA2015 is well-organised and has a good representation of exhibitors including group pavilions from Germany, Korea, Singapore, Taiwan and United Kingdom. Besides the key industry manufacturing solutions providers, our members also
22 | March-April 2015 | Medical Device ASIA
“Every edition of MTA has followed and highlighted industry trends relevant to Asian manufacturers and this edition is no different. We brought in exhibitors who showcased the latest innovation in 3D printing and robotics that will enhance productivity and efficiency. The technologies that MTA spotlights will certainly enable local and regional companies to move up the manufacturing value chain,” said Mr. William Lim, Project Director for machinery events at Singapore Exhibition Services, organiser of MTA2015.
Knowledge sharing with industry thought leaders Featuring case studies on digital manufacturing, Industrie 4.0 and industrial automation, the inaugural “Future Factories and Manufacturing Asia Conference”, provided in-depth knowledge and insight into the evolving business and industry landscape for Asian manufacturers.
Ms. Mazwin Mohd Rosli and Ms. Rozanatul Taneah Binti, managers at Tenaga Switchgear, Malaysia commented, “We were impressed with the excellent organisation of the show! We came to look for solutions that can be applied in Tenaga, and found products that were relevant to our business. We were keen on the assembly parts that were showcased at MTA2015, and met up with some potential suppliers such as Bilfort Industries, Cairnhill Metrology and Expresso System Technology for tooling and machining products. In addition, we are also exploring partnerships with some of the fabricators and CNC exhibitors who are looking for subcontractors. The Future Factories & Manufacturing Asia conference was interesting and we were able to gain insights on the technologies and solutions that other companies in the industry are using.”
More than 12,000 attendees from 41 countries/regions, including trade visitors, exhibiting staff, conference delegates and speakers, and members of the press visited MTA2015. The next edition of MTA will be held from 4 to 7 April 2017 at the Singapore Expo.
MTA 2015 SHOW PREVIEW
Mr Lee Yi Shyan, Senior Minister of State for Trade & industry and National Development examining a model car with Hexagon Metrology’s equipment
Ichi Seiki attracting the crowds with a demonstration of its GROB 5-Axis Universal Machining Center
Leaders in the industries they serve are present at MTA2015
Mr Lee Yi Shyan, Senior Minister of State for Trade & industry and National Development at the SIMTech booth at Capabilities Hub
Panel session at the Future Factories and Manufacturing Asia Conference
Speaker at the Future Factories and Manufacturing Asia Conference Medical Device ASIA | March-April 2015 | 23
The Grand Opening Ribbon-Cutting Ceremony
Surprising debut! MEDICAL JAPAN with MEDIX Triumphant success MEDICAL JAPAN 2015, Japan’s first comprehensive medical show, was held from February 4 to 6, 2015 at INTEX Osaka and made a surprising debut in the medical industry. Throughout the 3 day period, 723 exhibitors, 27,692 visitors, and 151 press/media professionals actively took part in the show for all sorts of medical products/services/ technologies for healthcare, clinical testing, diagnostics and medicine. The event was also supported by the Union of Kansai Governments, the Ministry of Health, Labour and Welfare in Japan, and 58 industry associations including Japan Hospital Association, the Japan Federation of Medical Devices Associations (JFMDA), the National Association for Home-visit Nursing Care. This comprehensive medical show consisted of 7 independent exhibitions: 1st [Hospital + Innovation] Expo Japan, 1st International Nursing & Nursing Care Expo (Nursing Expo Japan), 1st Clinical Laboratory & Diagnostics Expo Japan, 1st Regenerative Medicine Expo & Conference Japan, 5th Medical Device Development Expo Osaka (MEDIX OSAKA), 1st Int’l Pharmaceutical R&D and Manufacturing Expo/Conference (INTERPHEX OSAKA), 1st Int’l Pharmaceutical Ingredients Expo & Conference (in-PHARMA OSAKA 2015). On the first day of the show, MEDICAL JAPAN welcomed 40 powerful industry executives on stage at the Grand Opening Ribbon-cutting Ceremony to celebrate the opening of the longawaited exhibition around 1,000 exhibitors and visitors from Japan and all over the world.
24 | March-April 2015 | Medical Device ASIA
MEDICAL JAPAN 2015 organised by Reed Exhibition Japan Ltd. was hailed as a runaway success! Key figures - Remarkable achievement for a comprehensive medical trade show! • 723 exhibitors from 20 countries/regions • 27,692 visitors • Co-held Conference (total 221 presentations) attracted 14,111 attendees • 151 Press Registrants led to strong media coverage
MEDIX (Medical Device Development Expo Osaka) came back 2.7 times bigger in scale! Factors behind the success MEDIX OSAKA which took place within Manufacturing World Osaka until last year was renewed as one of the 7 exhibitions at MEDICAL JAPAN 2015. This dramatic change brought great benefits to exhibitors and visitors and led to the success of the show.
Major companies under one roof Major companies in the leading linear motion categories such as HIWIN, NIPPON THOMPSON and THK had outstanding booths which attracted many visitors. These exhibitors all gathered at MEDIX OSAKA, displaying technologies for robotic arms and other new products to grasp more business opportunities. In addition to these, major exhibitors of Manufacturing World, including Dassault Systèmes, a software company specialized in CAD, and Stratasys, a world leading 3D printing company, joined MEDIX OSAKA.
Local government established pavilion There were a significant number of exhibitors from “medical cities” such as Fukushima and Miyazaki where the medical device development is focused and supported by local governments. Some of the companies exhibited with government subsidies, as the Japanese government is encouraging new market entry and sales channel expansion for the economic growth of the country. By exhibiting at MEDIX OSAKA, they got the best opportunities to meet top leaders in person from various fields and expand their businesses globally.
MEDIX OSAKA - a must-attend show for medical device engineering. One of the prominent features that make MEDIX OSAKA more attractive is the quality of visitors. Valuable business meetings and networking
opportunities with people in powerful positions are conducted face-to-face. Indeed, many of the exhibitors pursued potential business deals onsite with those of wellknown manufacturers, including NIPRO, Sysmex, Olympus Medical, TERMO, Shimadzu, and KYOCERA Medical and many more.
Big wave of new comers Attendance of executives from large Japanese electronic corporations and newcomers from other industries was something that could not be seen at any other exhibition. Many of them have a great interest in healthcare business and recognise MEDICAL JAPAN as an important event to spot the newest developments and rising trends in the market. For example, there were a group of people from Panasonic Healthcare, a Panasonic group company involved in developing and manufacturing medical devices. Other major
home appliance manufacturers like SHARP and SONY also entered the market a few years ago by setting up healthcare business divisions. SONY executives in the Tokyo headquarters came all the way to Osaka for MEDIX OSAKA to break into this new business field. Daikin Industries, an innovative air-conditioning manufacturer, created their environmental medical device division recently and technical experts from the division attended the show to look for technologies that could be used for developing home care medical devices. Automobile companies are also stepping into the growing medical device market and MEDIX OSAKA attracted a large number of visitors from Toyota. The world’s top automaker has been developing electronic walking robots designed for rehabilitation purpose in the Partner Robotics division. One of the global automotive
Medical Device ASIA | March-April 2015 | 25
suppliers, Denso, also launched the Health Care division in recent years, utilizing automotive sensing technology and robotics technology to develop bio-sensing devices and medical devices. This clearly shows that healthcare business is not just for those involved in the medical industry, but many prestigious companies are seeking new business opportunities.
And organizational ability is not the only essential attribute for good exhibitions. Reed Exhibitions Japan Ltd. has a worldwide reputation for high-quality and large-scale exhibitions. It can be said that numerous users in the manufacturing industry were invited and attracted to this new medical show, because Manufacturing World Japan, one of the world’s largest manufacturing exhibitions, is also held by Japan’s largest trade show organizer.
MEDICAL JAPAN 2016 with MEDIX OSAKA will double its size with growth in participation of exhibitors in the fields of medical devices!
MEDICAL JAPAN 2016 A huge number of existing and new exhibitors signed up contracts for MEDICAL JAPAN 2016 during this year’s show period. The floor plans for the next show were displayed outside the exhibition halls and applicants selected booth locations on a first-come, first-served basis. Many booth spaces have been already reserved and the rest will be sold out soon. MEDICAL JAPAN 2016 will be twice larger in size with an increasing number of companies specialized in OEM technologies and 3D printing as well as manufacturers in the fields of electronic components and medical electronics. 1,200 exhibitors and 38,000 visitors are expected to participate in the show next year. MEDICAL JAPAN is the best gateway to get new technologies and market trends and will certainly have an important role for growth of the industry.
For more information about the exhibition, please contact Show Management. Website: www.medical-jpn.jp/en/ Email: medical-japan@reedexpo.co.jp 26 | March-April 2015 | Medical Device ASIA
MEDICAL JAPAN with MEDIX | SHOW PREVIEW
Medical Device ASIA | March-April 2015 | 27
Healthy Diet, Healthy Women
This Women’s Day take a vow to eat right and ensure your well being. Eating right go a long way for women, writes Kanika Malhotra, Senior Clinical Nutritionist, HealthCare at Home carbohydrates rich in fiber are a good source of energy supply as they get absorbed slowly. Other than this, the fiber in these meals reduces hunger, preventing you from overeating. Pasta, rice, whole grain breads, beans, fruits, and veggies are great source of complex carbohydrates which are also high on fiber content. Consume essential amount of fats: One thing that women, especially those conscious about their weight and looks, do grossly wrong is that they avoid food which has fat without knowing that it can lead to other problems like skin dryness. Even if they do consume fats, it is in the form of low fat food. Problem with low fat foods is that fat in it is replaced with starch, which is nothing but another form of sugar. So the result is not too different. It is imperative that you read the label properly before falling for the fad of low fat food. Eating almonds and walnuts is a good way to fill in the gap for fats. Get your food cooked in a combination of vegetable oils. Fifteen or twenty percent of total calorie intake should must be fat.
I
t iπø s no more a men’s world. Women are coming of age and becoming a part of everything that men are doing, and can possibly think of. Women had been versatile in their diverse roles of being a mother, sister, wife and friend. The roles are getting even bigger with the fairer sex storming into all the realms of professional spheres with poise. Their responsibilities are no more restricted to homes, they have expanded their arms to bring into their horizon myriad jobs and skills, which were till some decades back thought to be the stranglehold of only men folk. Women perform multiple roles with ease. However, when there are multifarious roles to take care of, ignorance of health is obvious . Irregular eating, consumption of junk food and missing meals are very common with working women. Sometimes, it is a natural phenomenon when pressure is high. But what they forget is that the after effects are seen at a much later stage, and by that time the damage to the body is already done. Healthy diet and nutrition is of utmost importance to women, given their bodies undergo many hormonal changes during puberty, pregnancy and menopause. A balanced diet provides enough support at all the stages. It helps to tackle Pre Menstrual Syndrome (PMS), boosts fertility, fights stress, makes pregnancy smoother , and eases symptoms of menopause. Things to take care of: Never miss your meal: Follow the essential three times a day meal and try to munch something healthy in between. Munching means taking anything healthy like a fruit or a salad. The repercussion of not eating is that you tend to go hungry all the more, and to satiate it, you eat unhealthy items. Only little thing that needs to be done is planning. The outcome of combination of balanced diet and exercise is lustrous hair, glowing skin and perfect shape. Complex carbohydrate and fiber intake: Ditching carbohydrate diet completely is something you should not think of. Meals having complex
28 | March-April 2015 | Medical Device ASIA
Avoid excess of sugar intake: Too much of sugary food lead to bloating and makes one feel heavy and lethargic. It also one of the reasons behind weight gain, blemishes and acne on face. It is good to stay away from sweets after meals and from binging on chocolates, cakes, desserts and other sweet items. Long gaps between meals aggravates craving for sugar. The best way is to not have long gaps and take mini meals in between the traditional three-time meal. You can also replace white rice and bread with those with brown ones. Take enough of calcium and iron: The risk of osteoporosis being higher in women, they need to consume enough of calcium for good bone health. Beans, broccoli, kale, brussels sprouts, and collard greens are perfect source for plant-based calcium. Iron is another essential element for women, especially during menstruation. For iron content, intake of lean red meat, dark poultry, lentils, spinach, iron-fortified cereals and almonds is advisable. Beware of excessive protein: While protein is important for body, too much of animal-based protein for women can cause harm as it leads to loss of calcium and decreases bone density. It is advisable that women opt for fish, skinless chicken, low-fat dairy, and plant-based protein sources, such as beans, nuts, seeds, peas, tofu, and soy products rather than red meat and processed meat. Reduce stress: Changing your lifestyle reduces your stress. Take an adequate sleep of 7-8 hours at least. Get organized, plan things and stop worrying! Lavender, chamomile tea, tulsi, mulethi are some of the herbs that help get rid of stress. Omega 3 fatty acids are known to reduce heart risk factors, stress and depression, so consumption of flaxseeds, unsalted pistachios, walnuts, almonds, salmon and tuna is advisable. Quit smoking and cut down on alcohol: Diet can play a major role in helping you quit smoking. Eating foods rich in vitamin C such as citrus fruits, capsicum, amla help in decreasing the urge to smoke. Keep your mouth busy with the help of a sugar free candy. Decrease your cravings to smoke by smelling on some dried fruits. Avoid alcohol and caffeine. Being a women comes with a lot of responsibility. That’s true for your health too!
Nutrition for Would-Be Brides
B
rides-to-be are always confused about what to eat and what not to eat. HealthCare at Home’s Senior Clinical Nutritionist Kanika Malhotra gives some insight into it.
Marriage season has set in again, busying hundreds, or may be thousands, of girls who have to take a plunge this time. Ask any of these girls what is that one thing they wish they had some more in the run up to their wedding and they, in all probability, will say –time. When there are innumerable things to take care of, the would-be-brides always run short of time. No matter how much time management is done to finish the planned tasks, there is something left unattended. Frenzy of a marriage is not easy to manage. In this hustle bustle, girls compromise with their eating schedules and end up skipping their meals, sometimes starving themselves, just to be able to avoid any last moment hiccups. When sometimes it happens under work pressure, there are also girls who do it deliberately with a view to reducing weight. However, what girls do not realize is that starving for whatever reasons will have adverse impact on health. Also, it might leave them looking dull, robbing them of all the bridal glow. When the stress to finish all the bridal-related work is at an all time high prior to the wedding, not being serious about eating can compound the situation. For this particular reason, as also for the sake of glow, it is important to ‘eat right’. So what things brides-to-be should stick to? Here is an insight to it: Never miss your meal: It is appreciated to be in shape before the wedding, but that should not happen at the cost of healthy diet. Losing extra flab is possible by eating right kind of diet, combining it with proper exercising regime. You can lose some kilos from targeted body areas under the guidance of a skilled fitness trainer. If you starve yourself with the intent to shed a bit of weight, then the approach is wrong. Follow the essential three times a day meal and also try to munch something healthy in between. Munching means taking anything healthy like a fruit or a salad. The repercussion of not eating is that you tend to go hungry all the more, and to satiate it, you eat unhealthy items. Only little thing that needs to be done is planning. The outcome of combination of balanced diet and exercise is lustrous hair, glowing skin
and perfect shape. Complex carbohydrate and fiber intake: Ditching carbohydrate diet completely is something you should not think of. Meals having complex carbohydrates rich in fiber are a good source of energy supply as they get absorbed slowly. Other than this, the fiber in these meals reduces hunger, preventing you from overeating. Whole wheat Pasta, Brown rice, whole grain breads, beans, fruits, and veggies are great source of complex carbohydrates which are also high on fiber content. Consume essential amount of fats: One thing that brides-to-be do grossly wrong is that they avoid food which has fat without knowing that it can lead to other problems like skin dryness. Even if they do consume fats, it is in the form of low fat food. Problem with low fat foods is that fat in it is replaced with starch, which is nothing but another form of sugar. So the result is not too different. It is imperative that you read the label properly before falling for the fad of low fat food. Eating almonds, flaxseeds and walnuts is a good way to fill in the gap for fats. Get your food cooked in a combination of veg oils. Fifteen or twenty percent of total calorie intake should must be fat. Avoid excess of sugar intake: Too much of sugary food lead to bloating and makes one feel heavy and lethargic. It also one of the reasons behind weight gains, blemishes and acne on face. Girls should stay away from sweets after meal and should not indulge in binging on chocolates, cakes, desserts and other sweet items. Long gaps between meals aggravates craving for sugar. The best way is to not have long gaps and take mini meals in between the traditional three-time meal. You can also replace white rice and bread with those with brown or multigrain ones. Drink lots of water: Drinking water helps to stay hydrated which has remarkable effect on skin by way of glow. When you are adequately hydrated, you do not overeat. Sometimes the hunger pang that you feel also is on account of you being just thirsty. Do not go overboard with eating and do not even limit yourself. Marriage is a time to celebrate and you should never sacrifice your food this time around. Remember, balancing is the only way out. Medical Device ASIA | March-April 2015 | 29
Cancer Genetics Expands Next-Generation Sequencing Capabilities In India
Through Launch of Solid Tumor Hotspot Panel For Biopharma and Clinical Customers Throughout Asia • • •
Over 370,000 patients in India develop solid tumor based cancers annually and are in need of more comprehensive genomic profiling The NGS panel assesses mutations across 50 actionable and clinically validated oncogenes and tumor suppressor genes with a higher level of sensitivity and specificity than existing methods Cancer Genetics will create a genomic database and information exchange of cancer hotspots that will help clinicians and researchers personalize and improve patient outcomes throughout India and Asia
C
ancer Genetics Inc. (Nasdaq: CGIX; “CGI” or “the Company”) announced recently that Cancer Genetics India (CG India) has launched a NextGeneration Sequencing (NGS) based panel targeting the five most common solid tumors: breast, colorectal, lung, skin, and ovarian cancer for the Indian and broader Asian markets. The NGS-based panel provides a comprehensive genomic assessment of cancer mutations, with dramatically increased sensitivity compared to other testing methodologies, and can be applied to over 370,000 patients annually in India alone. The NGS panel covers over 2,800 clinically validated, common cancer mutations and can be used from as little as 10 nanograms of DNA from a variety of sample types, including fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue. With more than 1 million new cases of cancer diagnosed in India each year, there is a significant need for NGS based comprehensive testing that provides both costsavings and increased accuracy over other technologies by assessing a comprehensive number of genetic mutations in a single test. The tests will also help CG India in its strategic initiative to generate a library of critical, actionable genomic data that can be used by clinicians for improved patient management and by researchers in India and worldwide to develop more targeted therapeutics. The International Agency for Research on Cancer (IARC) based in France predicts that the number of new annual cancer cases in India will double in the next 20 years only heightening the need for improved technology to help diagnose and manage cancers earlier and more comprehensively.
30 | March-April 2015 | Medical Device ASIA
“Cancer Genetics India’s NGS tumor hotspot panel will allow clinicians in India the capability to access the genomic information necessary to improve the diagnosis and management of patients with common cancers,” said Dr. Vidudala Prasad, Ph.D., Head of Research and Development at Indo American Cancer Hospital in Hyderabad, India. “It also offers valuable genomic insights for investigators working on oncology-focused clinical trials.” CG India is now one of few companies in India that is making this NGS technology and mutation hotspot panel available for use by oncologists, biopharmaceutical companies, and research organizations. Panna Sharma, CEO of Cancer Genetics, Inc. commented: “There is a critical need in India and Asia for highquality assessment of cancer that is comprehensive, genomically-guided and supported with state of the art bioinformatics. The clinical and research community will find tremendous value in both the NGS panel and in our genomic database which we expect will be an invaluable tool in the improvement of cancer outcomes for patients and in the acceleration of novel discoveries into the marketplace.” CG India is also in discussions with a number of biopharma and research companies in the formation of strategic collaborations and partnerships to use the NGS hotspot technology for discovery and accelerated research. The NGS panel addresses a significant, underserved
and growing market, and is expected to contribute to CG India’s overall growth. The use of the NGS hotspot panel will enable the collection of a large library of genomic data that can be used to improve the quality and accuracy of clinical research and discovery efforts. Mr. Sharma added: “CG India is among the first companies to launch NGS testing in India. This new panel further establishes us as a leader in DNA based diagnostics in India. With the launch of this new panel, we are in a unique position to deepen our collaborations and partnerships with major cancer centers, academic government institutions, and biopharma companies focused on oncology research.” About Cancer Genetics Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial SloanKettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.
Sweden: EUR 160m under InnovFin to support Getinge’s developments in medical technology About EIB The European Investment Bank (EIB) is the long-term lending institution of the European Union and is owned by the EU Member States. It makes long-term finance available for sound investment in order to contribute towards EU policy goals. In 2014, EIB financing in Sweden amounted to EUR 1.41 billion, with the main focus on projects promoting sustainable transport, energy efficiency and urban development.
GETINGE MEDICAL TECHNOLOGY II RSFF RDI investments related to medical technology in the areas of cardiovascular, critical care and surgical workplaces during the period of 2014-2017.
The European Investment Bank (EIB) has provided a EUR 160 million loan to Getinge AB, a global medical technology company, for its research and development in the areas of surgery, intensive care, infection control, care ergonomics and wound care. Getinge’s research addresses unmet medical needs and targets the development of new devices with higher efficiency and safety for increased positive outcomes for both caregivers and patients. In particular, the company aims at advancing its technology in the fields of cardiac surgery, cardiology, intensive care and emergency medicine. Further development will concern the area of critical care and surgical workplaces, including anaesthesia machines, continuous glucose monitoring and operating tables. Jonathan Taylor, EIB Vice-President with responsibility for lending in Sweden, stated: “We are pleased to be partnering with Getinge in this breakthrough operation as it enables the EU bank to support future technologies whose concrete applications will improve the health of European citizens. Projects such as this strengthen the competitiveness and boost the innovative capacity of European health-related industries and businesses, so enhancing Europe’s position as a major technology supplier and supporting skilled employment opportunities.” The project backed by the EU bank covers the entire research and development cycle from initial concept to clinical trials. It will be implemented until 2017 at the promoter’s research and development facilities located in Germany, Sweden and France, thus safeguarding the opportunities for the skilled workforce in these countries. Given Getinge’s collaboration with universities and public research programmes, the knowledge acquired through the research activities will also be widely disseminated across Europe. This is the first EIB operation in Sweden supported by the new generation of financial instruments for innovative and growth companies “InnovFin – EU Finance for Innovators”, with the financial backing of the European Union under Horizon 2020. The “InnovFin Large Project” facility is specifically dedicated to improving access to risk finance for research and innovation projects originating from larger firms in the European Union.
About Getinge Group Getinge Group is a global leading medical technology company that operates in the areas of surgery, intensive care, infection control, care ergonomics and wound care. Getinge Group has nearly 16,000 employees in over 40 countries and generates sales of almost SEK 27 billion (EUR 2.9 billion) (2014). The Group is divided into three business areas: Medical Systems, Extended Care and Infection Control – and operates under the brands of Maquet, ArjoHuntleigh and Getinge. InnovFin financial products Under Horizon 2020, the new EU research programme for 2014-20, the European Commission and the European Investment Bank Group (EIB and EIF) have launched a new generation of financial instruments and advisory services to help innovative firms access finance more easily. Over the next seven years, “InnovFin – EU Finance for Innovators” will offer a range of tailored products which will make available more than EUR 24bn of financing support for research and innovation (R&I) by small, medium-sized and large companies and the promoters of research infrastructures. This finance is expected to support up to EUR 48bn of final R&I investments. InnovFin builds on the success of the Risk-Sharing Finance Facility developed under the seventh EU framework programme for research and technological development (FP7), which financed 114 R&I projects to the tune of EUR 11.3bn and in addition provided loan guarantees worth over EUR 1.4bn. Backed by funds set aside under Horizon 2020 and by the EIB Group, InnovFin financial products support R&I activities, which by their nature are riskier and harder to assess than traditional investments, and therefore often face difficulties in accessing finance. All are demand-driven instruments, with no prior allocations between sectors, countries or regions. Firms and other entities located in EU Member States and Horizon 2020 Associated Countries will be eligible as final beneficiaries. These debt instruments will be complemented in the near future by a suite of equity instruments managed by the EIF. InnovFin Large Projects aims to improve access to risk finance for R&I projects emanating from larger firms, universities and public research organisations, R&I infrastructures (including innovation-enabling infrastructures), publicprivate partnerships, and special-purpose vehicles or projects (including those promoting first-of-a-kind, commercial-scale industrial demonstration projects). Loans and guarantees from EUR 25m to EUR 300m will be delivered directly by the EIB. Medical Device ASIA | March-April 2015 | 31
Quotient Clinical completes innovative first-in-human program
Q
uotient Clinical, the Translational Pharmaceutics® Company, has announced the publication of results from an Enabled-First-in-Human (Enabled-FIH) program conducted for the Janssen WAVE Early Development unit. The integrated pharmaceutical development and
productivity.” The results will be published on poster CT309 at the American Association of Cancer Research (AACR) 2015 Annual Meeting, Philadelphia, USA. 18-22 April 2015 (Millington DA, Chaplan SR, Aguilar Z et al. Rapid evaluation of a novel small molecule c-Met tyrosine kinase inhibitor in healthy subjects). For further information, please contact: Robin Bodicoat, Marketing Director, Quotient Clinical, Tel: +44 (0)115 931 5102, robin.bodicoat@ quotientclinical.com About Quotient Clinical
first-in-human clinical program was designed to develop an optimal oral formulation, in parallel with the assessment of single and multiple dose safety, pharmacokinetics and pharmacodynamics of a highly selective small molecule c-Met tyrosine kinase inhibitor. The clinical phase, which was conducted under a single, adaptive protocol, was completed in only six months. The single ascending dose phase began with a simple solution, and the protocol included the option to assess the relative bioavailability of up to two solid oral dosage formulations. The transition from solution to a solid dosage form was successfully achieved and this product was used to complete the remaining single and multiple doses. The clinical protocol also included flexible options to assess food effect, dosing frequency and administration to older subjects. Dose proportional increases in exposure were observed and all doses were safe and well tolerated. Mark Egerton, CEO of Quotient Clinical, commented: “We were very pleased to undertake this program. This is an excellent example of how our innovative Enabled-FIH service can support and accelerate an early development program. Timelines are shortened and the consumption of drug substance is reduced by >85 % compared to a conventional program, delivering significant cost savings. We believe that Enabled-FIH represents an important step forward in helping the industry to improve overall R&D 32 | March-April 2015 | Medical Device ASIA
Quotient Clinical offers unique services – based on its Translational Pharmaceutics® – that integrate formulation development, real-time drug product manufacturing and clinical testing, significantly reducing the time and cost of bringing a drug to market. For more than 20 years, Quotient Clinical has brought innovation to drug product development programs for pharmaceutical and biotechnology customers worldwide. The company is based in purpose-built, fully integrated facilities in Nottingham, UK, where formulation development, real-time GMP manufacturing and early clinical trials are performed in the same facility. It employs over 250 staff, offering a full range of support services, from study set-up right through to data analysis and reporting.
Flagship Biosciences Customizes Assay Development and Tissue Image Analysis for Advanced Cell Diagnostics RNAscope Platform - Flagship Biosciences and Advanced Cell Diagnostics collaborate to develop quantitative RNAscope® assays for pharmaceutical clinical trials in the CLIA environment - Flagship’s tissue image analysis addresses cell-based quantitation on the RNAScope platform RNAscope technology in CDx trials.
Westminster CO — Flagship Biosciences, the leading service provider of tissue image analysis solutions, announced today the utilization of its wet assay development and image analysis quantification capabilities for RNAscope® RNA in situ hybridization (ISH) from Advanced Cell Diagnostics, Inc. (ACD), a technology and market leader in the field of molecular pathology and developer of cell and tissue-based analysis tools. The two companies will work to optimize quantitative image analysis of in situ hybridization in tissue samples in Flagship’s CLIA laboratory.
T
he increasing use of RNA ISH in companion diagnostics for drug development and CDx strategies require multidisciplinary expertise in pathology, assay development and image analysis in a CLIA laboratory environment. Flagship has leveraged ACD’s industry-leading in situ hybridization assay platform to support its clients ongoing CLIA based clinical trials to enable the utilization of
“Flagship focusses on delivering unique fit-for-purpose quantitative pathology results, with advanced experience in both IHC and ISH assay development and custom image analysis. Over the last five years, our customers have benefited from our ability to focus our resources on unique scientific measurements using image analysis tools, which are able to overcome the obstacles barring clinical utility. By partnering with ACD, we are able to provide the state-of-the art in situ hybridization approaches, with quantitative endpoints suitable for a companion diagnostic strategy.” said Dr. Joseph Krueger, Chief Science Officer for Flagship Biosciences. “One critical feature of the RNAscope assay is its ability to detect individual RNA molecules within the context of tissue morphology. This enables a quantitative expression readout at individual cell level, which opens the door to a higher level of precision biomarker analysis,” said Dr. XiaoJun Ma, Chief Scientific Officer of ACD. “We are very pleased to work with Flagship to fully leverage this advantage, which is particularly important for the development of companion diagnostics.”
About Flagship Biosciences Flagship Biosciences, the industry leader in tissue image analysis, advances personalized medicine by quantifying and simplifying complex
pathology. The company utilizes proprietary “fit for purpose” image analysis solutions to transform conventional, subjective methods of histopathology into clear actionable data to speed global drug development and approval. Further information on tissue-based companion diagnostics can be found at www.flagshipbio.com.
About Advanced Cell Diagnostics Advanced Cell Diagnostics, Inc. (ACD) is a leader in the field of molecular pathology, developing cell and tissue based diagnostic tests for personalized medicine. The company’s products and services are based on its proprietary RNAscope® technology, the first automated multiplex chromogenic and fluorescent in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. RNAscope assays are currently used by all of the global top 10 pharmaceutical companies, world leading academic institutions and many cutting edge biotechnology companies to validate biomarkers for the management of cancer and other diseases. ACD’s industrial partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners’ targeted therapeutics. ACD also pursues internal programs to develop and commercialize proprietary diagnostic tests in cancer management. Learn more about ACD and RNAscope technology at www.acdbio.com.
Medical Device ASIA | March-April 2015 | 33
Regulatory and Clinical Factors Limiting US NonVascular Stent Market Growth, says GlobalData
T
he future growth of the non-vascular stent market by 2021 will be slower in the US than almost every other major market, due in part to an increasingly difficult regulatory process and the medical device excise tax, but primarily as a result of clinical factors and unmet needs still to be addressed, says research and consulting firm GlobalData. The company’s report* states that the US market for non-vascular stents, which includes enteral, airway, urinal tract, and pancreatic and biliary stents, was valued at $205.5 million in 2013. It is projected to expand at a modest Compound Annual Growth Rate (CAGR) of 3.3% to approximately $265.8 million by 2021. By comparison, the average CAGR across the 10 major markets, namely the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China, and India, will be 4.5%, and only Italy will witness slower growth than
the US over the forecast period, with a CAGR of 3.2%. Priya Radhakrishnan, GlobalData’s Director of Medical Devices, says restraints such as pricing pressures and regulatory hurdles will continue to have an impact on this market. Radhakrishnan says: “Despite the regulation there still remains some growth in all the markets, primarily driven by population, rising disease prevalence and expanding indications. Additionally, the growth in the elderly segment continues to keep the CAGR positive. “On the other hand, barriers to more heightened growth in the US, as opposed to the EU, include the slower adoption of newer stent technology, due to increased regulatory scrutiny by the Food and Drug Administration and an expensive product approval cycle.” GlobalData’s report also states that the medical device excise tax, which
34 | March-April 2015 | Medical Device ASIA
is a 2.3% US tax on the domestic sales of medical devices paid by the manufacturer, represents a costly and immense burden. Despite this, clinical factors remain the most prominent barriers to US market expansion. Radhakrishnan explains: “Factors such as a preference for minimally invasive solutions and a desire for better clinical outcomes will restrict
growth. “Opportunities that need further development include more customized, biodegradable and drug-eluting stents. As the complications are addressed in the next generation of products, we can expect to see further market expansion.” *MediPoint: Non-Vascular Stents – Global Analysis and Market Forecasts
ABOUT GLOBALDATA GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries. For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@globaldata.com.
Pregnancy aspects and being a New Mum As a new mum, we welcome you to the nine month long roller coaster ride known as pregnancy! Wandering just what you want to expect from the whole thing? point of your pregnancy as it is all downhill from here. During your sixth month, you can feel the baby’s the first kick and also need to change your prepregnancy wardrobe with beautiful maternity clothes of great shape. Seventh month brings to you stretch marks, and turning movement of your baby. You can also get crazy dreams. In your eighth month, movements will reduce and you are in the final stretch. Breathing becomes difficult and you don’t have the stamina to take long strides anymore. At full term, you cannot sleep comfortably: so take help of pillows or try different positions. Being a mother doesn’t mean that your life is over: in fact, it is the beginning of a new journey. As a new mum after delivery, you still look totally pregnant and will for some time. The uterus starts to contract in the postnatal period which leads to discomfort for few weeks. You are going to be making up for that bliss for the next month or so with something nasty called lochia pouring out of you faster than an extra super maxipad can keep up with. Try to remember that your baby is just a baby, not an alien. You are made to take care of this creature and you can do it really. If breastfeeding comes to you easily, consider yourself lucky and if you are struggling, take help of your lactation consultant or a support group from your hospital.
T
he moment a child is born, the mother is also born. She never existed before. The woman existed but the mother never. A mother is something absolutely new.
I was recently talking to my client who is also a new mum said, “You know all those things people tell you about being a new mum are actually true; those things that you heard and quickly dismissed as being not applicable to yourself and your unborn child”. While of course individual experiences vary, the common denominator cannot be escaped. Sharing experiences of our clients: In the first month of pregnancy for the first time, you might not even know that you are four weeks pregnant. Since, now you know that you are creating a new life, it is time to clean up dirty and fun habits (smoking, drinking etc). It is good to start making other mommy friends who can guide you and also convince you your pregnancy is normal. At two months of pregnancy, you must have realized that the term “morning sickness” is just bullshit but the sickness is round the clock. In the third month, your partner should know what you expect of him over the next six months. Fourth month is the best part of your pregnancy as you will start to look as if you are expecting: your hair is shining, skin will radiate the pregnancy glow and you have the courage to share this news with your friends and relatives. Fifth month is the halfway
Bonding with your baby is never immediate: it might take time but don’t worry if you don’t feel that maternal ooze of love. You can feel weepy due to change in hormonal levels, anxiety and exhaustion. If this feeling is more than baby blues, talk to your doctor: it can be a form of postpartum depression. The sooner you get the help, better it is. Things are not easy yet but, hopefully, you are finding some semblance of a groove by now. Babies love to be touched, and no matter what your mother-in-law might say, you are not going to spoil your month old infant by holding him/her too much. Better yet, wear your baby in a sling or carrier of some sort, so you can have a round around the house and your baby can feel close to you. Win/win all the way around. Your baby will make love stronger, your nights longer, days shorter, home happier, clothes dirtier, the past forgotten and the future worth living for. For you, as a new mum is the start of a new adventure: new challenges to face, new memories to make and new obstacles to overcome. Being a mother is learning about the strengths you didn’t know you had, and dealing with fears you didn’t know existed. Just giving birth to a child doesn’t make you a mother! Being a mother means taking care of your kids, cuddling, watching them grow, watching them play and argue, being there for the good and the bad, and most importantly showing them your unconditional love every second of EVERYDAY. I conclude by saying that “Being a new mum is one of the most rewarding blessings in the world”. Medical Device ASIA | March-April 2015 | 35
New four-way collaboration aims to improve clinical decision-making in the treatment of colon cancer Selah Genomics, Greenville Health System, DecisionQ Corporation and BD working together to “democratize genetic medicine” be based on both clinical and molecular annotation, so we’re very excited about this new collaboration.” Todd Radano, CEO DecisionQ added: “We look forward to working with our partners and applying our predictive analytic technology to help clinicians improve the way they treat colon cancer.” After proving the value for colon cancer, EKF and Selah Genomics intend to continue to evaluate similar models on other sites of origin.
E
KF Diagnostics subsidiary, Selah Genomics, has announced a major, four-way collaboration with Greenville Health System (GHS, South Carolina), DecisionQ Corporation (Virginia), and BD (Becton Dickinson and Company, New Jersey). Expected to last 18 months, the collaboration aims to unite classic clinical annotations with proprietary next generation sequencing (NGS) technology and artificial intelligence-based decision support algorithms in order to improve clinical decision support in the treatment of colon cancer patients. More than eight out of ten US patients are treated in the community, and as many as 60 percent of all patients with solid tumors do not respond to firstline treatment. This results in further treatment cycles, higher cost, elevated toxicity and, perhaps most importantly, lost time. A tool that significantly improves the prognostication for patients by bringing center of excellence expertise to any clinical setting is therefore highly desirable. Using its PrecisionPath™ NGS technology, Selah Genomics will first determine the genetic profiles of tumor samples provided by the Institute for Translational Oncology Research, which is part of GHS’s Cancer Institute. The samples, from colon cancer patients with known outcomes, will be provided with full clinical annotation. DecisionQ will employ its advanced machine-learning platform to integrate genetic profile data with clinical annotations to produce a model that will improve clinical decisions related to the treatment of colon cancer patients. The research project is being funded in part by BD in return for the first opportunity to license the technology should the collaboration be a success. After the initial collaboration, a clinical trial is planned to validate the research and affirm the effectiveness of the new system as a clinical decision support tool for the community-based setting. “This initial collaboration will demonstrate the power of a new generation of personalized medicine decision support tools for oncologists, starting with a particular focus on empowering oncologists treating colon cancer patients in the community-based setting,” said Michael Bolick, CEO, Selah Genomics. “Leveraging particular contributions from each of our partners, we have a unique opportunity to fast track our development timelines across an array of targets.” Jeff Edenfield, MD, Medical Director of GHS’s Institute for Translational Oncology Research said: “We have been using Selah Genomics’ PrecisionPath assay to provide molecular profiles of solid tumors since 2013. We share Selah’s vision that the determination of accurate tumor biomarkers needs to
36 | March-April 2015 | Medical Device ASIA
About EKF Diagnostics - www.ekfdiagnostics.com EKF Diagnostics Holdings plc, which includes the EKF Diagnostics, EKF Molecular, Stanbio Laboratory, Separation Technology Inc., DiaSpect and Selah Genomics brands, specializes in the development, production and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new molecular division, EKF Molecular Diagnostics, focuses on technology used within the development of companion diagnostics, specifically within oncology. EKF products are sold in more than 100 countries around the globe, through a network of specialist distributors. About Selah Genomics – www.selahgenomics.com Selah Genomics is a clinical diagnostic specialist supporting healthcare providers and the pharmaceutical industry with advanced molecular and genomic diagnostic services. Selah’s services add value to early stage drug development, clinical trials and regulatory processes in the pharmaceutical industry and helps clinicians and healthcare providers treat and monitor patients, thereby improving patient outcomes. With the Power of Precision, Selah Genomics provides the best in molecular diagnostic testing, assay validation and genomic profiling that all leads to one common goal: to provide better outcomes for patients. About GHS’s Institute for Translational Oncology Research With a focus on translational research and personalized medicine, ITOR of GHS provides some of the most advanced cancer treatments available anywhere in the world while supporting industry’s crucial need to achieve greater efficiency and expediency in bringing life-saving cancer drugs to patients. The effort to advance these goals led to the creation of ITOR – an evolutionary process that began in 2004. About DecisionQ DecisionQ Corporation is a predictive analytic company that uses its proprietary machinelearning technology to create the foundational insights that power many of today’s data discovery systems. Our predictive models are at work in many industries, including healthcare, consumer products, finance, national security, and marketing communications. About BD BD is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are more than 30,000 associates in 50 countries who strive to fulfill our purpose of “Helping all people live healthy lives” by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit www.bd.com.
Hitachi Aloka Medical, Ltd. introduces EggQus AOS 100E – a compact and lightweight Ultrasound Bone Densitometry System
Mr Minoru Yoshizumi, President of Hitachi Aloka Medical Ltd., Tokyo, Japan is pleased to announce the release of EggQus, an extraordinary compact, portable Ultrasound Bone Densitometry System at the European Radiology Congress (ECR). A new approach has been used in the development of the bone densitometry system, EggQus. It has been created using the design concept of an “eggshell”, a shape born in nature. Simply beautiful, strong, lightweight, easy to handle. All of these features guarantee maximum portability.
Outstanding portability* EggQus is light, compact and versatile compared to conventional ultrasound bone densitometry systems. The large integrated handle facilitates in-hospital rounds and house visits.
Rechargeable battery operation The system is powered by rechargeable batteries enhancing its portability. Continuous and convenient use can be sustained using the AC adapter accessory.
Easy operability The motor-controlled transducer unit moves automatically, minimizing manipulation by the operator.
Measurement in approximately three seconds The short measurement time is convenient for elderly examinees and for screening that requires rapid handling. EggQus is available for delivery from March 2015 (Shipment time may vary depending on regulation and registration of the country). * A computer is necessary for the measurement display. Please contact your vendor for further details.
About Hitachi Aloka Medical, Ltd. Based in Tokyo (Japan), Hitachi Aloka Medical, Ltd. is a subsidiary company of Hitachi Medical Corporation, also headquartered in Tokyo. The company delivers modern diagnostic ultrasound technology for medical doctors and patients. It resulted from a merger of Aloka Co., Ltd. and Hitachi Medical Corporation. Today, the company is one of the world’s largest ultrasound equipment suppliers and focuses on the three key areas medical electronic systems: diagnostic ultrasound, general analysis instruments (radiation measurement) and clinical laboratory systems (preparation of samples). Altogether, Hitachi Aloka has more than 60 years of experience in imaging diagnostics and is a global innovator in this domain. For more information about Hitachi Aloka Medical, Ltd., please refer to www.hitachi-aloka.co.jp. About Hitachi Medical Systems Europe Holding AG Hitachi Medical Systems Europe Holding AG, located in Zug, Switzerland, is a 100% subsidiary of Hitachi Medical Corporation, based in Tokyo, Japan. The company is a first choice supplier of open and powerful high-field MRI systems, multi-slice CT systems as well as medical ultrasound systems, bone densitometers and optical topography devices. Ultrasound expertise encompasses clinical applications including general radiology, internal medicine, obstetrics/ gynaecology, cardiology, gastroenterology, urology and surgery. Hitachi Medical Systems offer a complete range of solutions to address a wide range of medical challenges. For more information about Hitachi Medical Systems Europe Holding AG, please refer to www.hitachi-medical-systems.eu.
Medical Device ASIA | March-April 2015 | 37
Data presented at AACR 2015 recognizes value of EKF PointMan technology for assessing lung cancer mutation status
PointMan used for non-invasive analysis for T790M mutations of EGFR sequences, was used to successfully detect EGFR T790M mutations in the plasma DNA of advanced NSCLC patients. In all cases where T790M mutations were detected in tumour tissues, these mutations were also identified in plasma DNA.
PointMan™ DNA enrichment kit
D I A G N O S E
E
KF Diagnostics, the global diagnostics company, announces that its PointMan™ DNA enrichment technology has been identified as an easy and useful method for non-invasively determining plasma EGFR T790M mutation status in late stage lung cancer patients. This is according to data presented at the American Association for Cancer Research (AACR) Annual Meeting 2015, April 18 - 22, 2015, Philadelphia, Pennsylvania. In a scientific poster entitled, ‘Non-invasive analysis for T790M mutations of EGFR using a selective amplification method’[1], researchers from the Kanazawa University Hospital (Kanazawa, Japan) presented a study aiming to develop a blood-based, non-invasive approach to detecting the epidermal growth factor receptor (EGFR) T790M mutation. This is associated with EGFR tyrosine kinase inhibitor (EGFR-TKI) drug resistance in non-small cell lung cancer (NSCLC); where, generally, T790M positive patients have a much lower overall survival rate. Since tissue availability limits the genotyping of EGFR T790TM mutation in a clinical setting, a liquid biopsy-based approach would provide an ideal alternative to enable the identification of a potential change in treatment path in late stage lung cancer patients. The PointMan EGFR DNA enrichment kit, a novel method for selective amplification of genotype specific
38 | March-April 2015 | Medical Device ASIA
Andrew Webb, CEO EKF Molecular Diagnostics, commented, “These data presented at the AACR Annual Meeting 2015 provides a significant piece of independent evidence for the enabling of liquid biopsies for EGFR mutation detection in late stage lung cancer patients using our PointMan DNA enrichment technology. The use of such enrichment in a liquid biopsy will lead to improved clinical outcomes
for patients as we learn more about how mutation status changes during treatment.” The scientific poster presented at the American Association for Cancer Research (AACR) Annual Meeting 2015 is available to view at: http://www.ekfmolecular. com/system/resources/interfaces/ ContentDocument.ashx?id=228. For more information on EKF Diagnostics, visit www. ekfdiagnostics.com. Reference: 1. Nishikawa, S. et al. Non-invasive analysis for T790M mutations of EGFR using a selective amplification method. American Association for Cancer Research (AACR) Annual Meeting 2015.
About EKF Diagnostics
EKF Diagnostics Holdings plc, which includes the EKF Diagnostics, EKF Molecular, Stanbio Laboratory, Separation Technology Inc., DiaSpect and Selah Genomics brands, specializes in the development, production and worldwide distribution of point-ofcare blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new molecular division, EKF Molecular Diagnostics, focuses on technology used within the development of companion diagnostics, specifically within oncology. EKF products are sold in more than 100 countries around the globe, through a network of specialist distributors. Point-of-care diagnostics: EKF Diagnostics designs and manufactures world-class diagnostic devices, as well as distributing rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.
Pipeline Advancements and Asset Acquisitions Fueled Mid-Cap Biotech Research and Development Spend in 2014, says GlobalData
T
he combined spend on research and development (R&D) for the peer group of 35 mid-cap biotech companies increased by nearly $2 billion to reach a total of $9.7 billion in 2014, primarily thanks to top spenders Regeneron and Vertex, says research and consulting firm GlobalData. The company’s report* states that Regeneron led the way with R&D expenses of $860 million in 2013, with further analysis showing that Regeneron’s R&D expenses grew by 47.9% year-to-year to $1.3 billion in 2014. According to Adam Dion, GlobalData’s Senior Industry Analyst, this expenditure was boosted by an increase in clinical trial expenses, due to additional costs for studies of dupilumab, and REGN-1033, the company’s antibody to myostatin (GDF8), which is in Phase II trials for undisclosed musculoskeletal disorders.
Despite this, unexpectedly sharp rises in spending from Jazz and Alnylam helped to drive R&D in 2014.
Dion comments: “Regeneron’s R&D expenses also grew due to the fees for the regulatory submissions and marketing approvals for Eylea, which GlobalData forecasts to be the topselling eye drug by 2016. “However, Regeneron’s overall R&D cost burden was partly offset by the conclusion of the Phase III trials of Eylea in wet age-related macular degeneration and macular edema following central retinal vein
Dion continues: “Jazz’s 518% spike in R&D spend was the result of a $197 million surge of in-process R&D (IPR&D) expenses, due to the asset purchases of Aerial BioPharma and Sigma-Tau Pharmaceuticals. These purchases gave Jazz the rights to two promising drugs, namely JZP-110 for potentially treating aspects of narcolepsy and sleep apnea, and defibrotide, to prevent severe hepatic veno-occlusive disease in bone marrow transplant patients.
occlusion.” The analyst adds that Vertex had the second largest R&D outlay among the peer group, spending $855.5 million in 2014, representing a 3% decrease from 2013. This resulted from the company completing the TRAFFIC and TRANSPORT clinical trials evaluating VX-809, a combination product of lumacaftor and ivacaftor for treating cystic fibrosis.
“Meanwhile, Alnylam’s R&D expenses soared by 266% to $411 million in 2014, up from $112.3 million during 2013. This increase in R&D spend resulted primarily from a $221 million IPR&D charge in connection with Alnylam’s acquisition of Sirna Therapeutics’ RNAi assets from Merck,” the analyst concludes. *PharmaLeaders: Mid-Cap Biotechnology Benchmark Report – Sales Forecasts and Product Valuations of Innovative Biotechs ABOUT GLOBALDATA GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries. For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@globaldata.com.
Medical Device ASIA | March-April 2015 | 39
McCormack Pharma’s Landmark Discovery could mean New Guidelines for use of Anti-Platelet Drug
C
lopidogrel (Plavix) is an anti-platelet drug that is used to prevent the formation of a thrombus (clot) in vulnerable patients. However, a significant proportion of patients who receive clopidogrel remain at risk for subsequent death, myocardial infarction, stent thrombosis, and stroke because of insufficient clopidogrel-induced platelet inhibition. Using customized relational databases with the capacity to rapidly mine large volumes of data and identify previously-unknown relationships, McCormack Pharma provides a new insight into why some people fail to adequately respond to the life-saving effects of clopidogrel. Their report identifies free fatty acids as the final arbiter in determining the magnitude of clopidogrel resistance. Clopidogrel is a prodrug for an active metabolite that blocks the platelet P2Y12 receptor. This metabolite is generated in the liver by the cytochrome P450 (CYP) enzyme system. Inadequate responses to clopidogrel may be caused by polymorphisms in one or more of the cytochrome P450 enzymes, notably CYP2C19. However, when the mechanisms of clopidogrel resistance are explored across studies, polymorphisms in the CYP2C19 gene only partially explain the correlation with suboptimal clopidogrel response. Conversion of clopidogrel to the active metabolite is limited in patients who carry CYP2C19 loss-of-function polymorphisms. Insufficient amounts of active metabolite mean that some platelet P2Y12 receptors will remain functional. McCormack’s report defines points of convergence for potential augmentation of signalling from these remaining functional P2Y12 receptors by elevated levels of free fatty acids. This newly-characterized phenomenon fulfils requirements as a mechanism for non-linear augmentation of platelet activation. Additionally, McCormack’s analysis shows how, even with 100% blockade of the P2Y12 receptor pool, elevated free fatty acids can activate the platelet by
40 | March-April 2015 | Medical Device ASIA
mimicking the downstream events of P2Y12 signalling, and also by inducing the expression upon the platelet surface of a clopidogrelinsensitive pool of P2Y12 receptors. In clinical practice, these new findings offer an affordable solution for maximizing clopidogrel efficacy given that the use of inexpensive generic versions of clopidogrel is forecast to rise dramatically, in both developed and emerging nations. The report argues that in at-risk patient groups, the effects of an increased loading dose of clopidogrel are significantly attenuated by free fatty acids when above some critical concentration-dependent threshold. “In these patients attempts to maximize clopidogrel efficacy through stepping up the dose may be likened to a futile effort to slow a speeding vehicle through use of the brakes while the throttle remains wide open; concomitant lowering of free fatty acids levels is a straightforward solution ...... arguably, modulation of signalling by free fatty acids represents a highlycoordinated and teleologicallyconserved failsafe mechanism for maintaining signalling fidelity.” comments Dr Keith McCormack,
founder and Head of Research at McCormack Pharma. Dr McCormack emphasizes that McCormack Pharma’s conclusions and recommendations require validation before new guidelines are implemented. The complete version of the report is available on McCormack’s website at the URL below.
About McCormack Pharma and CEME The systems of correlation and association that formed the basis of McCormack’s data analysis platform CEME (Cutting-Edge Medical Education), were first created in 1983 by Keith McCormack. Today, CEME has evolved as a proprietary technology that is unique within the pharmaceutical industry. CEME describes the use of desktop methods that incorporate customized relational databases with the capacity to rapidly mine data and discover previously-unknown relationships between product data and data for a licensed indication. These novel outputs constitute new teachings that, by enhancing patient management provide the means for enhanced brand awareness and increased sales. More details are available atwww.mccormackpharma. com.
SNAPSHOT By Aleksey Vanin, MDpro
T
he Russian medical device market is estimated at $6.7 billion. It puts the country’s med-tech market among the top 15 in the world. In the 2000-2012 period the Russian med-tech market demonstrated stable growth of consumption because of increased government spending on health care. Today the Russian market is experiencing stagnation but it still presents many opportunities for foreign companies seeking to expand market share. Key characteristic of the Russian med-tech market is that the local demand for medical devices is mainly created by public purchasers and met mostly by foreign manufacturers.
Domination of public procurement Since most of Russian healthcare facilities are state owned, 75% of all medical devices are sold through a public bidding process. In many medical device categories the share of public consumption is approaching 85-90%. It is relevant to such segments as minimally invasive surgical devices, resuscitation devices, orthopedic devices, medical imaging devices and general surgery devices.
The Russian medical device market displayed a steady growth in the 2006-2012 period. It was the result of implementation of modernization programs, involving big investments in medical equipment purchasing. The biggest amount of money was spend on medical devices under regional modernization programs in 2011-2012 (around $4.5 billion). During this period, Russian public hospitals and clinics got used to purchasing of expensive medical devices of the world’s leading manufacturers. This “habit” was formed during the last 8-10 years. From 2013 onwards Russia’ economic growth has slowed down. It lead to a decrease of public funding of healthcare. As a result, the oversaturated medtech market deflated in 2013 – in certain segments demand collapsed to a 4050% of the 2012 level. As equipment sales were dropping in 2013, medical facilities’ budgets began to be redistributed towards maintenance of existing equipment (repair and expendables). This tendency was maintained in 2014.
Despite private healthcare system has been actively developing during the last 20 years, it still creates small demand for medical devices (around 25%). This figure consists mostly of purchases of medical devices and expendables for in vitro diagnostics, dental care and functional diagnostics. Strong dependence on imports The Russian med-tech market is supplied primarily by imports, as domestic companies tend to be small and undercapitalized. The share of imports to Russia grows year by year and in 2014 reached 86%. The bulk of imports come from Germany, USA, China and Japan (around 60% in 2014). Germany has been the leading importer of medical devices to Russia for the last five years, even though the global leader is USA. The largest importers of medical devices to Russia in 2014 were Johnson & Johnson, GE, Siemens, Roche and Fresenius Medical Care.
In April 2014 “The health care development program for 2020” was revised by the Russian government, which lead to funding reduction. Budget straits and halted public spending will allow satisfaction of only some of the demand for new equipment. In the next 3-4 years consumption of medical devices will be made up mostly of expendables and maintenance, without significant appropriations of new units. It is expected that market growth will be mostly inflationary in the coming years (around $6.5-6.7 billion), compensating for growing prices of medical devices and a sharp devaluation of the rouble. The market’s resurgence will occur after equipment purchased in 2011-2013 has run its 4-5 years service life – some time after 2017. They will have to buy cheaper equipment. Since domestic manufacturers are still no match for Western rivals, what is likely to happen is a shift of demand for equipment from the world’s leading manufacturers to second-echelon producers. Such companies will have good opportunities to grow their businesses in Russia. About the author: Aleksey Vanin is CEO of MDpro, a Russian market research and consulting company providing a wide range of intellectual services in the sphere of medical device market. Medical Device ASIA | March-April 2015 | 41
New solutions for back pain, one of the top three reasons for GP visits in the developed world Swiss medtech company Hocoma to launch the Valedo system for the first time in Asia, a departure from rehabilitation devices for neurological conditions. trunk and pelvis and transferring them to a monitoring device, the ValedoMotion provides quantitative assessments of movement and dysfunction allowing the therapist to tailor therapy. Precise and repeatable measurements enable an objective analysis and documentation of the patient’s therapy progress.
T
he Swiss medtech company Hocoma will be using conference and trade show RehabTech Asia 2015 to launch their Valedo Therapy Concept range in Asia. The Valedo system is a departure for Hocoma who are best known for rehabilitation devices for lower and upper limb disabilities caused by brain and spinal cord injuries, stroke, and other neurological conditions. Rather than neurological motor rehabilitation, the Valedo range, consisting of the ValedoShape, ValedoMotion and Valedo, are complementary products for a healthy back. Hocoma are potentially tapping into a huge market as back pain is ranked as one of the top three reasons for GP visits in the developed world with as many as 80 percent of us suffering from it at some stage in our lives. Its prevalence among workers in modern cities has led to an explosion in the numbers of chiropractors and osteopaths.
The Valedo range offers a hightech alternative based on clinical spinal assessments and computermonitored functional exercise training, which is made more fun for the patient by being incorporated into a virtual world computer game. Managing Director of Hocoma South East Asia and Singapore, Zen Koh says, “The Valedo Therapy Concept is effective because it is simple and fun to use. We will be launching it at RehabTech Asia and making it available to clinics in the region after that.” ValedoShape is a non-invasive device that provides precise, reliable spinal analysis with a high degree of data validity when compared to X-ray images. The resulting 3D graphics of the sagittal and frontal plane are easy to understand and can be used to support communication with the patient. Using wireless sensors attached to skin to record movements of the
42 | March-April 2015 | Medical Device ASIA
Accurate real-time visual feedback helps the therapist train correct movements and thus improve patient’s awareness of his movements. Immersion in a gamelike environment motivates patients to practice goal-oriented movements to control robot characters in different settings such as flying crosscountry or navigating an underwater world. While playing an avatar, one corner of the screen shows the patient’s spinal alignment and indicates if their posture is wrong, the movement is incorrect or the exercise is performed at the wrong speed. Once the patient has received oneto-one training from the therapist he can be left to continue, self-guided, allowing the therapist to supervise multiple patients at once.
The ValedoMotion was developed in collaboration with the team led by Prof. Dr. Jan Kool at Zurich University of Applied Sciences in Winterthur, Switzerland and is suitable for a wide range of patients including non-specific back pain, general muscular deficits of the trunk, malalignment of the spine such as in kyphosis, scoliosism or neurological conditions such as stroke, multiple sclerosis or Parkinson’s disease. The Valedo, a home version of the ValedoMotion, tackles the most common reasons for the failure of, or non-compliance with, therapy programmes outside the clinic: patient’s poor awareness of their own movements, incorrect execution of exercises and lack of motivation. The Valedo reminds patients to exercise, allows them to play the same exercise-based computer games on their iPads or iPhones, monitors and corrects their movements and reports the results back to the therapist. For more information visit booth C01 at RehabTech Asia 2015 or online at www.valedotherapy.com`
Dickies® launches complete range of Medical & Healthcare Uniforms & Foot Wear in India Leading global workwear brand Dickies® launched its medical & healthcare uniforms & footwear lines in India. The range of medical uniforms is affordable and durable, adhering to the brand’s motto – BUILT TO WORK. Dickies®, which began operations in India in November 2014, intends to bring quality and affordable workwear across industries in the country. The range of Medical & Healthcare uniforms is a part of the first phase of operations of the company. As the medical and healthcare industry in India continues to grow at a steady pace, there is a severe need for quality workwear for professionals across the board that ensures uniformity, quality and safety. Dickies® medical uniforms are designed keeping in mind the requirements of the professionals in the industry, who work long hours and are exposed to tough conditions. The uniforms, which include lab coats, scrubs and footwear, have easy-care fabric; cotton/polyester fabric that provides breathable, all day comfort and gender-specific sizing and styling. “There is a severe need for quality workwear in the Indian medical industry. The healthcare industry in India is expected to reach $160 billion by 2017, which means several thousand more people involved in servicing in this industry. Every industry needs durable, safe, affordable workwear – for safety, for better performance. Dickies hopes to fulfill this massive need for quality workwear in the Indian medical industry,” Mr. Ravi Karthikeya, CEO, Dickies India said. Williamson-Dickie Mfg. Co. is the world’s leading provider of authentic work uniforms, specializing in innovative performance work wear since 1922. The company offers premium quality products at an unmatched value across a vast assortment of uniforms, work & safety footwear in more than 100 countries. Williamson-Dickie operates in India through exclusive license with ID Overseas Pvt Ltd (A Group Company of India Designs Exports Pvt Ltd) This is accomplished globally by designing and producing high quality, fashion-inspired, comfortable medical uniforms and footwear. We create a warmer, friendlier, and healthier medical environment by providing dynamic, unique, and state-of-the-art products and concepts to help healthcare workers and their patients. Dickies medical & healthcare uniforms provide outstanding value, uncompromising quality, industry-leading style, and compassionate customer service in ethically produced and competitively priced for India. Every Dickies® product comes with “SATISFACTION GUARANTEED” commitment. Medical Device ASIA | March-April 2015 | 43
“Art & Culture” are well suited for all areas of healthcare Interview with Professor Erwin Wagner, Project Manager of “KulturStation” (English: Culture Station) of the University of Hildesheim Foundation
Theater, choir, photography – art and culture soothe the soul. Professor Erwin Wagner of the University of Hildesheim Foundation, who founded the “KulturStation” project together with the AMEOS Clinic, is sure of this. Patients and associates of the hospital’s psychiatric unit were involved in artistic activities. The goal was to improve well-being. After three years, Professor Wagner sums things up at MEDICA.de and reveals what he is most proud of.
Professor Wagner, what role do art and culture play in everyday hospital life? Erwin Wagner: They are not at all important or just very little. Sometimes hospitals use art and culture to attract interesting people when art exhibits are being organized for example. There are a few houses that truly produce art or create cultural forms in the hospital, but that
In the Theater Station, the participants have reinterpreted a Shakespeare play against the background of experience in psychiatry. With “Midsummer Night’s Dreams at the A7”, the theater group appeared two times; © KulturStation`
44 | March-April 2015 | Medical Device ASIA
still rarely happens. There are also types of entertainment that provide comic relief and distraction like the so-called hospital caring clowns, who primarily try to distract people from their illness and suffering and take their minds of things.
How did you come up with the idea to set up the KulturStation at the AMEOS Clinic in Hildesheim three years ago? Wagner: The stars were aligned, as is often the case in these instances. In this case, it was three people that came together at the right time: one colleague from the therapeutic field, another colleague, who had already tested a similar project in an experiment at another facility and I, who had consulted the hospital’s management. Together we came up with the idea to engage in art and culture together with patients and staff from the psychiatric unit to see what impact long-term projects have on well-being in everyday hospital life. There were different reactions from the management level. Some were excited about the idea. Others – particularly those who are in charge of finances – were initially somewhat reluctant. They were concerned whether this type of project could also cast a different light on the hospital – which is perfectly ok. They were hoping for more attention from the media and the public. And that is perfectly
acceptable.
The KulturStation consists of several individual projects. How were they organized? Wagner: Over the past three years, we were able to conduct different cultural projects. There were several concerts for example, dance, photography or theater workshops, light installations and exhibitions. A team at the hospital was in charge of organizing the individual events. So-called cultural couriers informed patients and employees of the different wards about our activities and promoted them and subsequently provided feedback on new ideas by interested parties. We then organized several projects on a small scale based on the requests and ideas by the participants. Aside from patients, hospital employees also joined in the projects – not quite to the extent we would have liked, but there were quite a few people involved and I thought that was great.
Which of the many individual projects are you most proud of? Wagner: Together with the Hildesheim Center for Pedagogy (German: Theaterpädagogisches Zentrum in Hildesheim), we were able to set up a theater group for two years, which staged a play and performed it two times. What’s more, the KulturStation developed a choir that also
activities work best to what extent and for which disease.
Did the project also have any commercial relevance for the hospital? Wagner: Here I would like to quote our former medical director, who once said, “we would not have achieved this amount of public attention, if we would have invested the money in a marketing department.” The public interest was therefore clearly noticeable though some definitely expected a lot more from this.
What conclusion do you draw after three years and what’s next for the KulturStation? Wagner: The project was definitely worth it. I am also very thankful that the hospital
got involved in the project and that we were able to implement it. Even though I will leave the project, it will continue. Marie Beisert, who was already a part of the coordination team, is going to take over its continuation starting next year. The findings and impressions, methods and networks we created together will continue to be used to introduce this idea to other hospitals and subsequently offer them as an individual product. We created two brochures as documentation. We work on spreading this idea in an adapted form to other healthcare fields, for instance in elder care or support. We believe that art and culture are always well suited for all areas of healthcare and can be both stimulating and useful.
regularly meets outside of the project and continues to sing together. I am particularly proud of this one.
What effect does culture have on a patient’s health? Wagner: Those, who participated in the various activities felt significantly better afterwards. After the events, we asked the participants to fill out questionnaires intended to provide feedback as to how helpful the projects were to them. We can conclude from these that both the participating patients and the employees of the psychiatric unit enjoyed the activities very much. This also boosted their well-being and self-confidence. However, we are not able to provide any scientific findings on which artistic Medical Device ASIA | March-April 2015 | 45
Metropolis announces launch of New Antibody Test for Major Kidney Disease Keeping pace with newer biomarkers in Autoimmunity- new antibody test launched for renal disease It is important to differentiate primary and secondary since the treatment and disease management varies. In Primary Membranous Nephropathy, an individual undergoes an immunosuppressive therapy or kidney transplant), whereas in secondary, the underlying disease is treated. PLA2R Antibody Test is used to correctly differentiate the two kinds of disease, evaluate the intensity of the disease, monitor therapy and risk assessment after kidney transplant.
O
ne of the major kidney diseases, Nephrotic Syndrome is defined by massive continued loss of urinary proteins and edema (water retention).
One of the major causes of Nephrotic Syndrome is Membranous Nephropathy or Membranous Glomerulonephritis which is a chronic inflammatory disease of the glomeruli (the network of capillaries in kidneys that perform the first step in filtering blood). In Membranous Nephropathy, an antibody-antigen complex otherwise called as the immune complex is formed in the glomerulus. This eventually leads to loss in kidney function and kidney failure. Membranous Nephropathy can be primary (where cause of the disease is not known; idiopathic) or could be secondary (as a result of an underlying condition like prolonged infection, tumor, cancer and even certain medications etc).
46 | March-April 2015 | Medical Device ASIA
Advantages of the test • Serum based test and requires only a blood sample • Easy to perform • Presents a non-invasive alternative to the common biopsy. • Anti-PLA2R autoantibodies are a highly specific and sensitive marker for primary MN. Additionally to its usage in differentiation of primary and secondary MN, the anti-PLA2R titer reveals a high predictive value for:
Disease evaluation Anti-PLA2R autoantibody results correlate with disease activity (proteinuria). High titers are directly proportional with a severe course of primary MN.
Therapy monitoring The anti-PLA2R autoantibody titer decreases in patients undergoing successful immunosuppressive therapy. A relapse of disease is
associated with a recurrence of the antibodies. Furthermore, a high anti-PLA2R titer was identified as a considerable risk factor for primary MN patients to not achieve a remission of proteinuria.
Risk assessment
Up to 40 % of patients with primary MN experience a relapse after kidney transplantation. This risk is particularly high if anti-PLA2R autoantibodies are persistently found during the six months after organ transplantation. Therefore, the titer can be useful to assess the necessity and intensity of an immunosuppressive therapy after transplantation to avoid relapses. Commenting on the test, Dr Deepak Sanghavi who heads the Immunochemistry section at Metropolis Healthcare said “It is an important test that will help improve outcomes and disease management in such a chronic kidney disease. We have tied up with few hospitals and Institute of Kidney Diseases and offer this test at INR 4,500. Out of the suspected samples that we receive, almost 4 out of 10 returns positive” About Metropolis Healthcare Ltd At Metropolis, what we believe is what we say and what we say is what we do. Being empathetic to our customers and being committed to their needs is in our DNA. Metropolis has grown to harness a culture that is open, synergistic, progressive and scientific in nature. We are the Pathology Specialists
delivering over 15 million tests a year, catering to more than 10,000 Laboratories, Hospitals, Nursing homes and 2,00,000 Consultants. With 33 years of experience in delivering accurate reports, Metropolis has earned the reputation of being India’s most respected and only multinational chain of diagnostic centres with presence in UAE, Sri Lanka, South Africa, Kenya, Mauritius and Ghana. Driven to make a difference, our wide network includes 125 state-of-art Laboratories across India with over 750 collection centres, processing over 4500
varieties of tests and supported by an efficient team of more than 3000 people. Equipped with cutting edge technology, innovative work equipment, expansive logistics network and rigorous processes, Metropolis ensures and delivers precision and accuracy in every single test; each time, every time. In the last 10 years, Metropolis has expanded into new service lines like Clinical Trials, Hospital Lab Management, Home Health Services, Preventive Health Check-ups and Corporate & Wellness Solutions. Metropolis is at the forefront in adopting cutting edge technologies and services that contribute new revenue streams and has positioned the company on the pedestal it is today. Today, we are one of the few laboratories
that has received the CAP (College of American Pathologists), accreditation, the global gold standard in Laboratory Accreditation. We have also received the NABL Accreditation (National Accreditation Board for testing and Calibration Laboratories). In addition, we also adhere to CLIA (Clinical Laboratory Improvement Amendments) program and follow the guidelines laid by GCP and GLP. Our unit in South Africa is accredited by SANAS (South African National Accreditation System is the
only accreditation body approved by South African Government). At Metropolis, we believe in unveiling the inner health of individuals and this motto extends to our corporate social responsibility activities as well. Giving back to the society is embedded in the value system of Metropolis and we believe and aim to bring about a positive change in the nation. Metropolis has been at the forefront in conducting impactful camps and driving numerous workshops for different sections of the society for the past 3 decades. We partner with societies, corporates, educational institutions, government bodies,
NGOs, wellness foundations and a host of other organisations to make a difference to the lives we touch. Our camps and awareness workshops emphasize on preventive healthcare and early screening of diseases. Some of our most recent associations include Epilepsy Foundation, Hep Free India, Mumbai Traffic Police, Kishori Foundation, Children of Blind School and JeevanJyot Cancer Trust. Metropolis has been awarded numerous accolades like the ‘Best Diagnostic Company of the year’ by Modern Medicare in 2006 and ‘Best Diagnostic Company of the Year’ in 2010 by Frost & Sullivan. Metropolis was also bestowed with ‘Best IT Integration in Customer Service Management’ at the e-Health World Expo 2011. Metropolis was also honoured with the ‘Quality Brand Award’ by NEHRDO in 2012. Metropolis won the ‘CMO Asia Award’ for Best IT practices in Healthcare in 2012. Metropolis recently bagged the ‘India’s most promising brand award’ at Global Indian Excellence Summit 2014 held in London. Metropolis Healthcare is led by Ameera Shah, Managing Director & CEO. An International & National Award winner, she was conferred with ‘The Young entrepreneur of the Year Award’ by GE in 2006 and ‘The Young Achiever of the Year Award’ at the CMO Asia Awards in 2011. She was also the recipient of the prestigious ‘Young Entrepreneur of the Year Award’ in 2011 organised by Entrepreneur India and Bloomberg. She has been honoured with ‘Exemplary Women Leadership award’ at the World Women Leadership and Congress awards 2014. Recently she has been chosen as one of the most respected leaders under 40 years by Economic Times & Spencer Stuart (2014). Metropolis Healthcare Ltd is funded by Warburg Pincus, a leading global Private equity firm.
Medical Device ASIA | March-April 2015 | 47
Fatty Liver Disease to surpass Hepatitis B & C as a cause for Liver Transplant & Liver Cancer • To emerge as major cause of liver failure • 2 Lakh people die annually in India due to end stage liver diseases • Launch of Fatty Liver Clinic to generate awareness about liver diseases Hepatology, Liver Intensive Care & Transplant Hepatology, Global Hospitals, Mumbai said, “Liver is the most important part of the human body which plays an important role in many bodily functions from protein production and blood clotting to cholesterol, glucose and iron metabolism. Almost 50% of the liver problem cases seen by us for evaluation of liver transplant had fatty liver disease. Out of these around 60% had NAFLD and 40% had Alcoholic Liver Disease. NAFLD could be caused by obesity, eating junk food, lack of exercise, Diabetes, high cholesterol, metabolic syndrome etc. About 3 to 4 out of 10 Indians have fatty liver which is often ignored or people are not even aware that they have it. Spotting the trend, we realized that FLD will be a major cause for liver failure very soon. WHO on the occasion of World Health Day has adopted the theme of Food Safety – From Farm to your Table. Improper and untimely snacking, bingeing and sedentary lifestyle, with little or no exercise are causing lot of liver diseases.”
T
he Hepatology team at Global Hospitals one of the fastest growing chains of multisuper specialty, multi-organ transplant and quaternary care Hospital in India has found in their day to day practice that the incidence of liver failure has increased in patients suffering from Fatty Liver Disease (FLD) as opposed to patients with Hepatitis B & C. Liver diseases are the 9th leading cause of death in India next only to diabetes. Experts in Global Hospitals have discovered that more and more cases of liver failure are happening due to FLD; and the incidence of liver failure due 48 | March-April 2015 | Medical Device ASIA
to Hepatitis B & C is declining gradually. Another interesting fact is that the number of patients with Non- Alcoholic Fatty Liver Disease (NAFLD) are increasing compared to alcoholic fatty liver disease. There are over 100 types of liver diseases and most of these diseases are called silent killers as they have a long gestation period. Speaking about Liver Diseases, Dr. Samir Shah - HOD,
Dr. Ravi Mohanka - Chief Surgeon and HOD, HepatoPancreato-Biliary Surgery and Liver Transplantation said, “Due to vaccination for Hepatitis B and effective medications now available for both Hepatitis B and C, the incidence of liver failure due to them has been on decline. Alcoholic and non-alcoholic Fatty Liver Disease could also lead to cancer and liver cancer is the 3rd leading cause of cancer related deaths in the world. If this damage is not controlled at
this stage by lifestyle changes, it may progressively lead to liver cirrhosis, requiring a liver transplant. The problem becomes more complex due to the fact that the numbers of organ donors are very less compared to people in need of a transplant. On an average, it may take few months to a year to get a liver for cadaveric transplant. It is also common to find family members of patients to have fatty liver and therefore not suitable for living donor transplant.� Taking cognizance, Global Hospital Mumbai will be opening a Fatty Liver Clinic. It will offer comprehensive and holistic liver care at one place. Consultations with experts in hepatology, endocrinology, dietetics, physical trainers, liver and bariatric surgeons will be followed by a patient specific plan. They will be given nutritional goals, exercise goals and monitored closely, evaluated periodically to check the health of their liver. Dr. Shah said that experts will also deliver talks and conduct camps to create awareness about the menace
of liver disease in the general public as well as in the corporate sector through various initiatives. We would be visiting the societies in the vicinity and educating the residents of causes of liver disease and preventive measures to be taken. We will also be targeting schools during their Parents Teachers Association gatherings and create awareness among parents as well children. We would be encouraging more and more people to come forward for organ donation.
About Global Institute of Liver Diseases, HPB Surgery and Transplantation, Mumbai
The Global Institute of Liver Diseases, HPB Surgery and Transplantation at Global Hospitals Mumbai have a State-of-the-Art facility that specializes in management of liver-related issues. Global Hospitals is one of the most comprehensive centers for liver, pancreas diseases & transplantation in India. The Institute brings an exceptional team of expert doctors from multiple disciplines to provide personalized care and the most advanced treatment options to patients with all types of liver conditions and diseases. The HPB & Liver transplant program at the Global Hospitals is headed by
Prof. Mohamed Rela, a Guinness Record Holder for his achievements in the sphere of liver Transplantation. Dr. Samir Shah as the Head of the Dept. of Hepatology along with a cohesive team of Hepatologists, HPB Surgeons, Anesthetists, HPB radiologists and Liver pathologists make the team of Mumbai. A comprehensive 15 bedded Liver Transplant ICU, and 2 dedicated Liver Transplant and HPB Operation Theaters are part of this unique lifesaving initiative of the Global Hospitals, Mumbai. In liver transplantation, Global Hospitals have a success rate which is at par with the best in the world, thus making them a natural choice for patients ailing from hepatic illnesses across India and the globe.
About Global Hospitals Group
Global Hospitals Group is one of the fast growing chains of multi super specialty tertiary care Hospitals in India offering healthcare services of international standards. With over 2000 beds, the Group currently has state-of the art and world class hospitals offering advanced patient care, at Hyderabad, Chennai, Bangalore and Mumbai. With the most comprehensive multi-organ transplant services in the country, the Group has carved out a niche for itself by excelling in areas ranging from simple procedures to complex surgeries and multi-organ transplantation services for liver, pancreas, kidney heart and lungs. It has evolved to become a one-stop healthcare destination for people from across the world. Recognized for internationally reputed doctors and cutting-edge medical technologies, the Group’s Hospitals have achieved several milestones by performing rare, pioneering surgeries and transplantations. Global Hospitals Group is also spearheading advanced stem-cell research and academic programs. Please visit: http://www. globalhospitalsindia.com/
Medical Device ASIA | March-April 2015 | 49
Xenex Germ-Zapping Robots Arrive in Spain; Clece Chooses Xenex for Hospital Disinfection
Xenex Disinfection Services recently announced that Clece, Spain’s leading healthcare provider of cleaning, maintenance, catering and social services, has chosen Xenex Germ-Zapping Robots™ for room disinfection at hospitals in Spain and Portugal. Clece has deployed Xenex robots at the Vall d’Hebron University Hospital in Barcelona, where they will be used to supplement the hospital’s cleaning and disinfection procedures. Clece will also implement Xenex robots at Ramón y Cajal in Madrid. 50 | March-April 2015 | Medical Device ASIA
Infections caused by superbugs like Clostridium difficile (C.diff), Methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE) are a global problem and Xenex is a proven solution to destroy the deadly microorganisms before they can bring harm to patients and healthcare workers. Xenex’s germ fighting robots take cleaning and decontamination to the next level by using pulsed xenon, an environmentallyfriendly inert gas, to create full spectrum, high intensity ultraviolet (UV) light that quickly destroys infectious germs. The robot destroys C.diff spores and other microorganisms in less than five minutes, and Xenex has peer reviewed, published outcome studies showing a greater than 50 percent decrease in C.diff, MRSA and multi-drug resistant organism (MDRO) infections when those hospitals used the Xenex robots to disinfect rooms.
use in hospitals worldwide as we have patented protocols for use in multi-bed wards. The robot’s speed enables it to disinfect areas and rooms quickly so it can be used throughout the entire facility, including multi-bed wards, to enhance patient and healthcare worker safety.”
“Xenex germ-zapping robots are already in use in nearly 300 hospitals in the United States, with infection rate reductions reported in several medical journals. We have been very diligent about our international expansion and ensuring that we find the right partners who share our passion for patient safety. We congratulate Clece for bringing this technology to Europe and we look forward to global deployment of our robots to stop the suffering caused by hospital acquired infections,” said Mike DelVacchio, Senior Vice President of Sales and Marketing at Xenex. “Xenex is ideal for
“The Xenex robots will complement our current methods of cleaning and disinfection of surfaces in hospitals. There are many UV disinfection technologies out there, but only Xenex doesn’t contain mercury bulbs and is proven and published in peer reviewed journals to work in the hospital environment and reduce infections. We will use the robots for the terminal room cleaning of patients infected or colonized with multi-drug resistant microorganisms, because those rooms pose the biggest threat to patient safety,” said José Luis Muñoz Garrid, Director de Hospitales de Clece.
The Xenex robot is designed for speed, effectiveness and ease of use, which allows Clece’s cleaning staff to operate the robot without disrupting hospital operations. With a proven five-minute disinfection cycle, the robot can disinfect 30-62 hospital rooms per day (according to Xenex customers), including patient rooms, operating rooms, equipment rooms, emergency rooms, intensive care units and public areas. Nearly 300 hospitals, Veterans Affairs, DoD, skilled nursing facilities, ambulatory surgery centers and long-term acute care facilities in the U.S. use Xenex robots.
“Being able to provide hospitals with this proven technology is an example of Clece’s commitment to innovation and excellence in service. The Xenex robots are capable of destroying nonenveloped viruses in just minutes, so they will play a major role in our infectious disease outbreak protocols.” According to Clece, the main advantages of Xenex’s robot are: Provides a fast, safe and effective method of disinfection. Preserves the health of healthcare workers and hospital employees by providing thorough disinfection of all surfaces. Uniquely designed for ease of use and portability, Clece’s staff can operate the Xenex robot via an intuitive interface without interrupting the normal operation of the hospital. The robot’s quick five-minute disinfection cycles enable them to use it in many
rooms per day. Environmentally-friendly disinfection technology that uses no chemicals and does not contain toxic mercury. No safety or disposal issues associated with mercury bulbs.
Young, Rich?
The Only UV Disinfection Device Proven to Work in the Hospital Environment. In the last four years there have been 10 peer reviewed studies published confirming the efficacy of the Xenex GermZapping Robot in the healthcare environment, including three studies showing a decrease in C.diff, MRSA and/or MDRO infections in patients when the hospital utilized the Xenex robot for room disinfection. Xenex is the only UV disinfection provider that has hospital customers publishing infection reduction results in peer-reviewed journals, most with greater than 50 percent decreases in their HAI rates.
A new survey shows that younger, richer and better educated people are less worried about data privacy than other Americans.
About Xenex Disinfection Services
Xenex’s patented pulsed xenon Full Spectrum UV room disinfection system is used for the advanced disinfection of healthcare facilities. Due to its speed and ease of use, the Xenex system has proven to integrate smoothly into hospital cleaning operations. The Xenex mission is to eliminate harmful bacteria, viruses and spores that can cause hospital acquired infections in the patient environment, and to become the new standard method for disinfection in healthcare facilities worldwide. For more information, visit www.xenex.com.
About Clece
Clece is a multi-company leader in providing integrated services to companies. With nearly 70,000 employees and a presence throughout Spain, including 11,000 employees in Catalunya, CLECE provides cleaning services, maintenance, energy, logistics, airport and social services and other professional services for all types of institutions and companies across all sectors.
You Are Less Likely To Worry Over Healthcare Data Privacy
Truven Health Analytics and National Public Radio conduct a monthly poll of 3,000 Americans on various healthcare topics and the November survey reveals that 68% of Americans overall would be willing to share their health information anonymously with researchers. But demographics made for interesting variations in the results. Among millennials the willingness to share information was higher - 72.6%. The same goes for people under 35 74.7%. Meanwhile, the comfort level of information sharing with researchers, even anonymously, declined with age - only 60.3% of people who were 65 and older were willing to do so whereas only 58.6% of the silent generation, the generation preceding the baby boomers, were open to sharing their data.
more privacy with
Among the wealthy - those who made $100,000 annually - there wasn’t as much concern about data privacy with 73.1% open to sharing data while people whose annual income was less than $25,000 a year were concerned about data 67% agreeing to share information. Better people were also more say yes to sharing their information. The poll 68.9% of those advanced
educated likely to healthcare found that with an degree beyond college were open to sharing data whereas 64.9% of those with high school or less were comfortable with doing so. But when it came to sharing information with doctors, hospitals and insurers from their social media behavior and credit card purchases, most Americans were deeply reluctant even if the information was meant to improve their overall health. Predictably 84% of those who were 65 or older said no to sharing that information while 69.6% who were 35 and younger echoed that sentiment. Interestingly, while age and generation had the above distinction in terms of level of discomfort, there was not as much gap in the “no” responses of people despite different education and income levels. It appears that healthcare data is less bogged down by concerns of privacy compared with financial data and personal information on social media. Medical Device ASIA | March-April 2015 | 51
52 | March-April 2015 | Medical Device ASIA
COMPANY PROFILE Rhenus Logistics Rhenus as a Group has an annual turnover of over Euro 4 Billion with more than 24,000 employees catering to various Logistics needs of the companies globally.
verticals with expertise in subject matter provide logistics solutions for a large variety of shipments encompassing almost all industry segments including Electronic Goods, Chemicals, Pharmaceuticals, and Automobile Industry etc.
Their business areas are Contract Logistics with specialization in multiple Industry Verticals, Freight Logistics in all modes like Air, Ocean, Rail & Road, and Port Logistics with presence in both deep sea Ports and Inland Ports in European hinterland and Public Transportation.
They are a highly quality conscious Company with accreditation of ISO 9001, EMS 14001 & OHSAS 18001. They have also received TAPA certification for Domestic Trucking and the first trucking Company to do so.
Rhenus Logistics India: In India Rhenus is a Joint Venture with the “Arya” Family. The historical roots of the company date back to Western Arya Group, which is an off-shoot of the Arya Family of Companies operational since 1947 (over 6 decades). The current shareholders are 3rd Generations Entrepreneurs from the larger Arya Family with over 20 years of experience in managing a basket of services to forward looking customers in India. They offer complete customized Logistics Solutions to their customers for their entire Supply Chain and have a distinctive advantage as compared to their competition as all services are provided with their In-house capabilities with highest quality and safety norms. Living up to its Vision of “achieving leadership status as a Totally Integrated Logistics Company” the group in India has added various innovative products in its basket keeping in mind the needs of its customers. Currently Rhenus Logistics India presence across all major gateways in India with capabilities to offer Freight Forwarding, Warehousing & Distribution; Value added Services as well as Foreign Trade Management Services (FTMS). Stream Line Logistics Private Limited, a 100% subsidiary of Rhenus Logistics India offers Customs Clearance services across gateways. Rhenus Logistics India has the distinct advantage of PAN India presence to cover Full truck load shipping, Less truck load shipping, and Express, Milk runs as well as other transport related services. Rhenus Logistics has about 1.1million square feet of Warehousing space and offices at strategic locations with ability to scale up at short notice. Today, they are one of the very few companies in India who offer end to end logistics services and are a ONE STOP SHOP solution for the customer. Customer Service and Customer Orientation is the cornerstone of their business model and their team always ensures that they go an extra mile towards achieving customer Delight. They believe that the major differentiators compared to their competitors today in their business are PEOPLE, TECHNOLOGY & focus on QUALITY. They have invested in all of these, in the past few years and will continue to do so in the future. Cutting edge HR initiatives like training and development, career counseling, coaching and mentoring, grooming are rolled out on a continuous basis. Rhenus Logistics India has strength of over 800 professionals with the lowest attrition rate in the industry. Professionally qualified employees across 54 | March-April 2015 | Medical Device ASIA
They provide valuable solutions through group synergy, as each project has its own requirements, they design individual services to form specially customized service packages - even for unusual tasks.
Profile Vivek Arya, Managing Director at Rhenus Logistics India P. Ltd Mr.Vivek Arya is the Managing Director at Rhenus Logistics India. He manages the Indian arm for Rhenus Logistics which is involved in Logistics, Freight Forwarding, Warehousing services and Shipping. Rhenus as a Group has an annual turnover of over Euro 4 Billion with more than 24,000 employees catering to various Logistics needs of the companies globally. The services offered by his company cover the entire process chain; from procurement of raw materials to distribution of finished products. Mr. Arya is a graduate from the Mumbai University. He has been involved in the family business of trucking which started in the late 1940’s by his Grand Father. He is a third generation entrepreneur. He had the opportunity to be trained in the business under his father Late C M Arya. He has now been involved in the business for over 25 years and has transformed the family trucking business into a full-fledged Integrated Logistics Company. His flagship Company Rhenus Logistics India of which he is a Managing Director is a Joint Venture with large Multi Billion German based Group. The Indian operations of the Company employs 800 people offering world class services customized to suit every customers need.
Enter the entire Asian region:
140,000+ show scale
--------------------------30,000+ senior pharma professionals --------------------------100+ countries represented --------------------------80+ onsite features --------------------------9 events in 1 --------------------------2,800 exhibitors Pharmaceutical Machinery
Packaging Material
Contact: Ms. Tina Zheng Tel: +852-2827-6211 Email: pmec-hk@ubm.com www.cphi-china.cn/en
Laboratory Equipment
24-26 June 2015
Clean Technology
CRO & CMO
SNIEC
Biopharmaceutical
Shanghai, China
Natural Extracts
Pharma Logistics
Government of India, Registrar of Newspapers of India (RNI)#: DELENG/2009/30008
Join us on the 10th Anniversary of China's Leading Pharma Machinery Platform